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SUMMARY 
 
Drak2 is a member of the death-associated protein family, and is a serine threonine kinase. In 
Drak2 null mutant mice, T cells have no apparent defect in activation-induced apoptosis after 
stimulation with anti-CD3 and anti-CD28, but have a lowered threshold to stimulation, compared 
with wild type (WT) T cells.  
In our study, in situ hybridization analysis has revealed that Drak2 expression is ubiquitous at the 
mid-gestation stage in embryos, followed by more focal expression in various organs in the 
perinatal period and adulthood, notably in the thymus, spleen, lymph nodes, cerebellum, 
suprachiasmatic nuclei, pituitary, olfactory lobes, adrenal medulla, stomach, skin and testes. We 
generated Drak2 transgenic (Tg) mice using the human β-actin promoter. These Tg mice showed 
normal T cell versus B cell and CD4 versus CD8 populations in the spleen, but their spleen 
weight cellularity was lower in comparison with wild type mice. After TCR activation, the 
proliferation response in Drak2 Tg T cells was normal, although their interleukin (IL)-2 and IL-4 
but not interferon-γ production was augmented. Activated Drak2 Tg T cells demonstrated 
significantly enhanced apoptosis in the presence of exogenous IL-2. At the molecular level, 
Drak2 Tg T cells manifested a lower increase of anti-apoptotic factors during activation; such a 
change probably rendered the cells vulnerable to subsequent IL-2 insults. The heightened 
apoptosis in Drak2 Tg T cells was associated with reduced numbers of T cells with the memory 
cell phenotype (CD62Llo) and repressed secondary T cell responses in delayed type 
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hypersensitivity. These results demonstrate that Drak2 expresses in the T cell compartment but is 
not T cell-specific; and it plays critical roles in T cell apoptosis and memory T cell development. 
 
Further, we investigated the role of Drak2 in β-cell survival and diabetes. Drak2 mRNA and 
protein were rapidly induced in islet β-cells after exogenous inflammatory cytokine or free fatty 
acid stimulation, which is present endogenously in either type 1 or type 2 diabetes. Drak2 
upregulation was accompanied by increased β-cell apoptosis. The β-cells apoptosis caused by 
the said stimuli was inhibited by Drak2 knockdown using siRNA. Conversely, transgenic (Tg) 
Drak2 overexpression led to aggravated β-cell apoptosis triggered by the stimuli. Drak2 
overexpression in islets compromised the increase of anti-apoptotic factors, such as Bcl-2, Bcl-
xL and Flip, upon the cytokine and free fatty acid stimulation. Further in vivo experiments 
demonstrated that Drak2 Tg mice were prone to type 1 diabetes in a multiple-low-dose 
streptozotocin-induced diabetes model, and they were also prone to type 2 diabetes in a diet-
induced obesity model. Our data show that Drak2 is detrimental to β-cell survival.  
 
We also investigated the signalling pathway of Drak2. We found that purified Drak2 could 
phosphorylate p70S6 kinase in an in vitro kinase assay. Drak2 overexpression in NIT-1 cells led 
to enhanced p70S6 kinase phosphorylation, while Drak2 knockdown in these cells reduced the 
phosphorylation. These mechanistic studies proved that p70S6 kinase was a bona fide Drak2 
substrate in vitro and in vivo. 
 
This study has discovered the important functions of Drak2 in T cell homeostasis and diabetes. 
We proved that p70S6 kinase was a substrate of Drak2. Our findings have broadened our 
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knowledge of Drak2 in the immune and endocrine system. Some of our findings, such as the 
roles of Drak2 in memory T cell development and β cell survival could be explored for clinical 
application in the areas of transplantation and diabetes.  
 
 
 
 
 
 
 
 
 
Key words:  Drak2; transgenic; memory T cell; apoptosis; islet; diabetes. 
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Résumé 
 
 
Drak2 est un membre de la famille des protéines associées à la mort et c’est une sérine/thréonine 
kinase. Chez les souris mutantes nulles Drak2, les cellules T ne présentent aucune défectuosité 
apparente en apoptose induite par activation, après stimulation avec anti-CD3 et anti-CD28, mais 
ont un seuil de stimulation réduit, comparées aux cellules T de type sauvage (TS).  
Dans notre étude, l’analyse d’hybridation in situ a révélé que l’expression de Drak2 est ubiquiste 
au stade de la mi-gestation chez les embryons, suivie d’une expression plus focale dans les divers 
organes pendant la période périnatale et l’âge adulte, notamment dans le thymus, la rate, les 
ganglions lymphatiques, le cervelet, les noyaux suprachiasmatiques, la glande pituitaire, les 
lobes olfactifs, la médullaire surrénale, l’estomac, la peau et les testicules. Nous avons créé des 
souris transgéniques (Tg) Drak2 en utilisant le promoteur humain β-actine. Ces souris Tg 
montraient des ratios normaux entre cellules T versus B et entre cellules CD4 versus CD8, mais 
leur cellularité et leur poids spléniques étaient inférieurs comparé aux souris de type sauvage. 
Après activation TCR, la réponse proliférative des cellules T Tg Drak2 était normale, même si 
leur production d’interleukine (IL)-2 et IL-4 mais non d’interféron-γ était augmentée. Les 
cellules T Tg Drak2 activées ont démontré une apoptose significativement accrue en présence 
d’IL-2 exogène. Au niveau moléculaire, les cellules T Tg Drak2 ont manifesté une augmentation 
moins élevée des facteurs anti-apoptotiques durant l’activation; un tel changement a 
probablement rendu les cellules vulnérables aux attaques subséquentes d’IL-2. L’apoptose 
compromise dans les cellules T Tg Drak2 a été associée à un nombre réduit de cellules T ayant le 
phénotype des cellules mémoires (CD62Llo) et avec des réactions secondaires réprimées des 
cellules T dans l’hypersensibilité de type différé. Ces résultats démontrent que Drak2 s’exprime 
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dans le compartiment des cellules T mais n’est pas spécifique aux cellules T; et aussi qu’il joue 
des rôles déterminants dans l’apoptose des cellules T et dans le développement des cellules 
mémoires T. 
En outre, nous avons recherché le rôle de Drak2 dans la survie des cellules β et le diabète. 
L’ARNm et la protéine Drak2 ont été rapidement induits dans les cellules β de l’îlot après 
stimulation exogène par les cytokines inflammatoires ou les acides gras libres et qui est présente 
de façon endogène dans le diabète, qu’il soit de type 1 ou de type 2. La régulation positive de 
Drak2 a été accompagnée d’une apoptose accrue des cellules β. L’apoptose des cellules 
β provoquée par les stimuli en question a été inhibée par la chute de Drak2 en utilisant petit 
ARNi. Inversement, la surexpression de Drak2 Tg a mené à l’apoptose aggravée des cellules β 
déclenchée par les stimuli. La surexpression de Drak2 dans les îlots a compromis l’augmentation 
des facteurs anti-apoptotiques, tels que Bcl-2, Bcl-xL et Flip, sur stimulation par la cytokine et 
les acides gras libres. De plus, les expériences in vivo ont démontré que les souris Tg Drak2 
étaient sujettes au diabète de type 1 dans un modèle de diabète provoqué par de petites doses 
multiples de streptozotocine et qu’elles étaient aussi sujettes au diabète de type 2 dans un modèle 
d’obésité induite par la diète. Nos données montrent que Drak2 est défavorable à la survie des 
cellules β.  
Nous avons aussi étudié la voie de transmission de Drak2. Nous avons trouvé que Drak2 purifiée 
pouvait phosphoryler p70S6 kinase dans une analyse kinase in vitro. La surexpression de Drak2 
dans les cellules NIT-1 a entraîné l’augmentation de la phosphorylasation p70S6 kinase tandis 
que l’abaissement de Drak2 dans ces cellules a réduit la phosphorylation. Ces recherches 
mécanistes ont prouvé que p70S6 kinase était véritablement un substrat de Drak2 in vitro et in 
vivo. 
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Cette étude a découvert les fonctions importantes de Drak2 dans l’homéostasie des cellules T et 
le diabète. Nous avons prouvé que p70S6 kinase était un substrat de Drak2. Nos résultats ont 
approfondi nos connaissances de Drak2 à l’intérieur des systèmes immunitaire et endocrinien. 
Certaines de nos conclusions, comme les rôles de Drak2 dans le développement des cellules 
mémoires T et la survie des cellules β, pourraient être explorées pour des applications cliniques 
dans les domaines de la transplantation et du diabète.  
 
 
 
Mots clés : Drak2; transgénique; cellule mémoire T; apoptose; îlot; diabète. 
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I. INTRODUCTION 
 
 
Act Against Allergy web-site, SHS International Ltd  
Fig.1. Innate and adaptive immune system: The mechanisms of innate immunity provide the initial 
defense against infections. Adaptive immune responses develop later and consist of activation of 
lymphocytes. 
 
 
An immune system is a collection of mechanisms that kill pathogens and tumor cells, 
as well as distinguish them from the organism's own healthy cells and tissues. It can 
be divided into innate and adaptive immune system (Fig.1). The innate immune 
system is usually triggered when microbes are identified by pattern recognition 
receptors, which recognize components that are conserved among broad groups of 
microorganisms. Innate immune defenses are non-specific, and do not confer long-
lasting immunity against a pathogen. The adaptive immune system is stronger and 
also has immunological memory, where each pathogen is "remembered" by a 
signature antigen. The adaptive immune response is antigen-specific and requires the 
recognition of specific “non-self” antigens during a process called antigen 
presentation. The cells of the adaptive immune system are special types of leukocytes, 
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called lymphocytes. B cells and T cells are the major types of lymphocytes and are 
derived from hematopoietic stem cells in the bone marrow. B cells are involved in the 
humoral immune response; T cells are involved in cell-mediated immune response.  
T lymphocytes consist of functionally distinct populations, the best defined of which 
are helper T cells and cytolytic, or cytotoxic, T lymphocytes (CTL). Most helper T 
cells are CD4+, and most CTLs are CD8+. 
CD4+ lymphocytes, or helper T cells, are immune response mediators, and play an 
important role in establishing and maximizing the capabilities of the adaptive immune 
response. Helper T cells express T cell receptors (TCR) that recognize antigen bound 
to major histocompatibility complex (MHC) Class II molecules. The activation of 
CD4+ T cells requires engagement of the TCR and CD28 on the T cell by the MHC 
and B7 family members on the antigen presenting cell (APC). Both singals are 
required for production of an effective immune response. The activation of a naive 
helper T-cell causes it to release cytokines, which influences the activity of many cell 
types. Helper T cells can provide extra signals that "help" activate cytotoxic cells. 
Cytotoxic T cells induce the death of cells that are infected with viruses (and other 
pathogens), or are otherwise damaged or dysfunctional. Naive cytotoxic T cells are 
activated when their T-cell receptor (TCR) strongly interacts with a peptide-bound 
MHC class I molecule. Once activated, the CTL undergoes a process called clonal 
expansion in which it gains functionality, and divides rapidly, to produce effector 
cells. Activated CTL will then travel throughout the body in search of cells bearing 
that unique MHC Class I peptide. To limit extensive tissue damage during an 
infection, CTL activation is tightly controlled and generally requires a very strong 
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MHC/antigen activation signal, or additional activation signals provided by helper T-
cells. Upon resolution of the infection, most of the effector cells will die and be 
cleared away by phagocytes, but a few of these cells will be retained as memory cells. 
T lymphocytes originate from hematopoietic stem cells in the bone marrow and seed 
the thymus. The thymus is the major site of maturation of T cells.  The earliest 
thymocytes express neither CD4 nor CD8, and are therefore classed as double-
negative (CD4-CD8-) cells. As they progress through their development they become 
double-positive thymocytes (CD4+CD8+), and finally mature to single-positive 
(CD4+CD8- or CD4-CD8+) thymocytes that are then released from the thymus to 
peripheral tissues. About 98% of thymocytes die during the development processes in 
the thymus by failing either positive selection or negative selection, whereas the other 
2% survive and leave the thymus to become mature immunocompetent T cells. 
Positive selection "selects for" T-cells capable of interacting with MHC. Double-
positive thymocytes (CD4+/CD8+) that bind the MHC/antigen complex with adequate 
affinity will receive a vital "survival signal." The thymocytes with low affinity die by 
apoptosis, and are engulfed by macrophages. 
Negative selection removes thymocytes that are capable of strongly binding with 
"self" peptides presented by MHC. Thymocytes that survive positive selection 
migrate towards the boundary of the thymic cortex and thymic medulla. While in the 
medulla, they are again presented with self-antigen in complex with MHC molecules 
on APCs such as dendritic cells and macrophages. Thymocytes that interact too 
strongly with the antigen receive an apoptotic signal that leads to cell death. The vast 
majority of all thymocytes end up dying during this process. This process prevents the 
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formation of self-reactive T cells that are capable of generating autoimmune diseases 
in the host. 
 (Molecular Biology of the Cell; Fourth Edition) 
 
1. T cell homeostasis and apoptosis 
 
T cells are the most versatile cells in the body. The homeostasis of T cells plays an 
important role in the immune system (1). 
T cells rest in peripheral lymphoid organs until they encounter activating signals, such 
as foreign antigen presented by antigen-presenting cells. They will undergo clonal 
expansion and differenciation and gain the ability to enter sites of inflammation. To 
maintain homeostasis after clonal expansion, activated T cells must be removed once 
the invading antigen has been eliminated (2). Only a few T cells that have been 
exposed to the antigen remain and develop into memory T cells. These memory cells 
will respond rapidly to subsequent exposure to the same antigen and are resistant to 
death by apoptosis (3;4). 
 
1-1 T cell apoptosis  
The peripheral T cells go to apoptosis by several mechanisms. Caspases have a central 
role in the regulation and execution of most types of apoptotic cell death. All caspases 
are catalytically inactive zymogens and will undergo proteolytic processing after 
activation (5). The initiator caspases (also known as apical caspases) are activated 
first, then they activate the effector caspases. It is generally accepted that activation of 
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initiator caspases takes place in large protein complexes that bring together several 
caspase zymogens (6). All initiator caspases are characterized by the presence of a 
stretch of 80–100 amino acids, which is called death domain (DD). The DD 
superfamily includes the DD subfamily, the death-effector domain (DED) subfamily 
and the caspase-recruitment domain (CARD) subfamily, which enables the 
recruitment of caspase into the initiation complex. Following dimerization in the 
initiation complex, initiator caspases are activated. They then cleave and activate the 
effector caspases, mainly caspase-3, caspase-6 and caspase-7.  
Activation of the caspase cascade results in the cleavage of a number of important 
cellular proteins, known as the 'cell-death substrates'. Cleavage of nuclear lamins 
results in chromatin condensation and nuclear shrinkage; cleavage of the inhibitor of 
the caspase-activated DNase (ICAD) results in the release of the endonuclease, which 
travels to the nucleus to fragment DNA. Cleavage of cytoskeletal proteins, such as 
actin, plectin, and gelsolin, leads to cell fragmentation, blebbing, the formation of 
apoptotic bodies and the destruction of the cell. The dying cells express 'eat-me' 
signals, such as phosphatidyl serine and different surface sugars, and are removed by 
phagocytes (7).  
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           Youle, R. J. and Strasser, A. (2008) Nat.Rev.Mol.Cell Biol. 9, 47-59 
           Fig 2. Intrinsic and extrinsic pathway of apoptosis: The intrinsic pathway (left) starts with BH3-only 
protein induction or post-translational activation, which results in the inactivation of some BCL-2 
family members. This relieves inhibition of BAX and BAK activation, which in turn promotes apoptosis. 
Some BH3-only proteins, such as BIM and PUMA, may also be able to activate BAX and/or BAK (as 
shown by the dotted line). Once activated, BAX and BAK promote cytochrome c release and 
mitochondrial fission, which leads to the activation of APAF1 into an apoptosome and activates 
caspase-9 to activate caspase-3. Caspases in turn cleave a series of substrates, activate DNases and 
orchestrate the demolition of the cell. The extrinsic pathway (right) can bypass the mitochondrial step 
and activate caspase-8 directly, which leads to caspase-3 activation and cell demolition. The BCL-2 
family regulates the intrinsic pathway and can modulate the extrinsic pathway when cleavage of BID 
communicates between the two pathways. 
 
In lymphocytes, caspase activation and subsequent apoptosis may be induced by two 
distinct pathways. One is called the intrinsic, or mitochondrial, pathway of apoptosis, 
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which is associated with mitochondrial permeability changes. The other is called the 
extrinsic pathway of apoptosis, which is associated with signals from death receptors 
in the plasma membrane (Fig.2). Intrinsic apoptosis is passive cell death which results 
from loss of survival stimuli and extrinsic apoptosis is activation-induced cell death 
mediated by death receptors.  
1-1-1 Extrinsic cell-death-receptor and caspase-dependent apoptosis 
In the extrinsic apoptotic pathway, pro-apoptotic signals are delivered through cell-
death-receptor-adaptor molecules to their ligands, such as tumour-necrosis factor 
(TNF), CD95 ligand (CD95L; also known as FASL) and TNF-related apoptosis-
inducing ligand (TRAIL). The cell-death receptors, defined by the presence of a DD, 
include several members of the TNF receptor (TNFR) superfamily: TNFR1, CD95 
(also known as FAS or APO-1), TRAIL receptor-1 (TRAILR1), TRAILR2, death 
receptor 3 (DR3) and DR6 (8-10). The transduction of the apoptotic signal from the 
cell-death receptors assembled a structure on the plasma membrane that is known as 
the DISC (death-inducing signalling complex). After the death domain is activated, 
further pro-apoptotic signals are delivered through caspase cascade. For example, 
CD95L bind to CD95, then leads to the formation of the CD95 DISC, which activate 
caspase-8 and caspase-10.  
There are two types of CD95-mediated extrinsic apoptotic signalling pathways (11). 
Type I: Cells are characterized by high levels of CD95 DISC formation and high 
amounts of active caspase-8. Activated caspase-8 and caspase-10 directly lead to the 
activation of downstream effector caspase-3, caspase-6 and caspase-7. 
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Type II: There are lower levels of CD95 DISC formation, therefore, lower levels of 
active caspase-8. In this case, signalling requires an additional amplification loop, 
which involving the molecules from mitochondria. In this loop, caspase-8 cleaved Bid 
into truncated Bid (tBid). Subsequently, tBid releases cytochrome c from the 
mitochondria. The release of cytochrome c from the mitochondria results in formation 
of a large protein complex, called apoptosome. Apoptosome activates pro-caspase-9, 
which in turn allows caspase-9 to cleave the downstream effectors pro-caspase-3, pro-
caspase-6 and pro-caspase-7. CD95 signalling in Type II cells can be blocked by Bcl-
2 family members, such as Bcl-2 and Bcl-xL.  
 
1-1-2 Intrinsic mitochondria and caspase-dependent apoptosis 
In the intrinsic pathway of apoptosis, the caspase cascade can be triggered by several 
stimuli, including TCR stimulation, UV-irradiation, DNA damage, endoplasmic 
reticulum (ER) stress, hormones (such as glucocorticoids) and cytokine deprivation. 
This pathway crucially depends on permeabilization of the outer mitochondrial 
membrane (12;13). Mitochondrial membrane permeabilization results in the release of 
mitochondrial content, such as cytochrome c. Cytochrome c and cytoplasmic 
apoptotic-protease-activating factor 1 (APAF1) form the protein complex apoptosome. 
At apoptosome, the initiator pro-caspase-9 is recruited by the interaction of CARD 
with APAF1. Then caspase-9 is activated and leads to the activation of the effectors 
caspase-3, caspase-6 and caspase-7. Therefore, the extrinsic and intrinsic apoptotic 
pathways converge at the level of the effector caspases.  
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The release of apoptogenic factors from mitochondria is regulated by the interaction 
of a group of pro- and anti-apoptotic members from Bcl-2 family (14)(Fig.3). 
Structurally, members of the Bcl-2 family contain up to four conserved homology 
domains (BH-domains), and optionally a transmembrane segment. Bcl-2, Bcl-xL, 
Bcl-w, Mcl-1, A1, and CED-9, the homolog in C. elegans, share the BH domains 1–4 
and promote cell survival, while mammalian Bax, Bak, Bok, and D. melanogaster 
DEBCL/DROB are related to Bcl-2 at BH1–3, and promote cell death. There is 
another sub-class of pro-apoptotic Bcl-2 family members, the BH3-only proteins: 
mammalian Bad, Bik, Blk, Hrk/DP5, Bid, Bim, Noxa, and C. elegans EGL-1. They 
share with their relatives only the short BH3 interaction domain (13). Apoptosis is 
initiated by the BH3-only Bcl-2 family members. And pro-apoptotic Bax and Bak act 
downstream in this pathway. Notably, Bid works as a conection between death-
receptor pathway and the mitochondrial route of apoptosis. As mentioned before, 
upon CD95-ligation, Bid is cleaved by caspase-8 and migrates to the mitochondria to 
promote the release of cytochrome c. There is also evidence showing that Bid directly 
interactes with Bax and Bak. 
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Strasser, A. (2005) Nature Rev.Immunol. 5, 189-200 
Fig 3. Mammalian BCL-2 family member: The pro-survival family members — BCL-2, BCL-XL, BCL-
W, A1, MCL1 (myeloid-cell leukaemia sequence 1) and BOO (BCL-2 homologue of ovary) — each 
have two or four distinct BCL-2-homology (BH) domains. The pro-apoptotic members of the BCL-2 
family can be subdivided into at least two groups: the BAX /BAK-like proteins — BAX, BOK (BCL-2-
related ovarian killer), BCL-XS and BAK; and the BH3-only proteins — BAD, BIK, BID, HRK 
(harakiri), BIM, NOXA, PUMA and BMF (BCL-2-modifying factor) — which share with each other 
and other members of the BCL-2 family only the short (9–16 amino acid) BH3 domain.  
 
 
After an infection is cleared, most T cells generated during the clonal expansion phase 
are removed through either of two apoptotic pathways, termed activation-induced cell 
death (AICD) and activated cell autonomous death (ACAD). AICD is thought to 
depend mainly on an extrinsic form of apoptosis induced by the ligation of death 
receptors such as Fas on the surface of the T cell. ACAD is thought to depend on an 
intrinsic form of cell death which is regulated by Bcl family (15). 
 
1-1-3 Activation-induced cell death (AICD)  
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TCR restimulation of already expanded T cells in the absence of appropriate co-
stimulation may also lead to the efficient induction of cell death. This is called 
activation-induced cell death (AICD) (16;17).  
AICD involves stimulation through CD95 (18;19) TNFR1 (20) TRAILR (21-23) and 
other mechanisms independent of cell-death receptor (24). Some findings suggest that 
TNF is involved in the late phase of AICD (25). AICD can be mimicked by an in vitro 
model system using TCR-activated T cells cultured with IL-2 and restimulated 
through the TCR or by PMA and ionomycin (26). 
After approximately 4 to 7 days of TCR restimulation in vitro culture results in the 
expression of CD95L (27-29). This induces CD95-mediated cell death either of the 
same cell (suicide) or of neighbouring cells (fratricide). The induction of CD95L 
expression requires calcium mobilization and production of reactive oxygen species 
(ROS) which is mediated by protein kinase Cθ (PKCθ) (30). Therefore, the CD95 
system has been considered to be an important regulator of T-cell homeostasis. Mice 
with decreased levels of CD95 or mutations in the gene encoding CD95L (lpr or gld 
mice, respectively) produce autoantibodies and develop lymphoproliferative disease 
(31;32). However, specific deletion of the gene encoding CD95 in all T cells leads to 
lymphocyte depletion and pulmonary fibrosis-like disease (33). Therefore, CD95 
inactivation in T cells alone is not sufficient for the pathogenesis of 
lymphoproliferation. These results indicate that in addition to the CD95 system, there 
are other CD95-independent AICD pathways that regulate T-cell homeostasis. 
After TCR triggering, the expression of Bim is also increased, which suggests Bim is 
a mediator of AICD as well. Upregulation of Bim expression by TCR triggering 
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depends on the activities of p38 and JNK, and may also involve PKC and calcium 
signaling (24). 
Non-caspase proteases have also been implicated in T-cell death. A serine protease 
called granzyme B plays a role in AICD of TH2 cells but not of TH1 cells (24). 
Granzyme B is an effector molecule of cytotoxic T cells which is located in 
intracellular lytic granules (34). Subsequently, granzyme B was found to be 
upregulated in response to TCR stimulation in TH2 cells and led to AICD which was 
independent of CD95–CD95L engagement. In granzyme-B-deficient mice, AICD was 
abrogated in TH2 cells. And the accumulation of TH2-cell-associated cytokines 
increased their susceptibility to allergen-induced asthma. 
It has further been shown that in epithelial cells, lysosomes are also involved in the 
execution of cell death (35).  Lysosomal proteases, such as cathepsin B, are activated 
by proteolytic processing as a result of lysosomal stress and are released into the 
cytosol. Cell death by cathepsins might involve the mitochondria (36;37), or cell-
death-receptor stimulation (38).  
 
1-1-4 Activated cell-autonomous death (ACAD)  
Autonomous cell death occurs in the absence of appropriate survival signals such as 
cytokine deprivation or by neglect. This is called activated cell-autonomous death 
(ACAD) (39). 
Bim is essential for ACAD. The expression of Bim or PUMA increased after cytokine 
deprivation (40). On the mitochondrial membrane, Bim or PUMA can bind Bcl-2 or 
Bcl-xL, which abrogates the inhibition of Bax or Bak and results in cytochrome c 
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release and the induction of T-cell death (41;42). During the expansion phase T cells 
can switch from a Bcl-xL high to a Bcl-xL low state, which allow the activation of the 
intrinsic apoptotic pathway (43). Bad also plays a role in activating or enhancing 
apoptosis in cells removed from required cytokines. In the presence of cytokines, Bad 
is phosphorylated by kinases such as Akt, PKA, and Rsk and is sequestered by 14-3-3 
proteins in the cytosol. Upon removal of cytokine, Bad is dephosphorylated and 
translocates to the mitochondria, where it binds Bcl-2 and Bcl-xL and inhibits their 
antiapoptotic function (15). 
 
1-2 T cell memory 
Prior to contact with antigen, naive T cells congregate in the secondary lymphoid 
tissues (spleen, lymph nodes, and Peyer's patches) and migrate continuously from one 
lymphoid organ to another via blood and lymph (44). After encountering pathogens, 
naive T cells go through clonal expansion and differentiation into effector cells. In a 
typical viral infection, this will last 7–10 days until the pathogen is eliminated. After 
that, these activated T cells will undergo clonal shrinkage to keep T cell homeostasis. 
The disappearance of activated T cells at the end of the primary response involves two 
distinct mechanisms, death and homing to nonlymphoid tissues. First, many of the 
activated T cells leave the spleen and localize in nonlymphoid tissues, notably the 
lungs, liver, and gut (44). Second, in both lymphoid and nonlymphoid tissues, the 
majority of the T cells (90–95%) die within 5 days, those cells that survived become 
memory cells (45) (Fig.4).  
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          Fig 4. Inflammatory cytokines and CD8+ T-cell homeostasis after infection: Antigenic peptides 
presented naive CD8+ T cells trigger their proliferative expansion and differentiation into effector 
CD8+ T cells.5–10% of CD8+ T cells detected at the peak of the expansion survive the contraction 
phase and initiate the memory CD8+ T-cell pool. The contraction phase is diminished in the absence of 
inflammation (for example the absence of IFN ) or when the balance and activation state of pro- and 
anti-apoptotic BCL-2 family members expressed by CD8+ T cells is altered. Diminished contraction 
results in increased numbers of memory CD8+ T cells. 
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Based on the expression of homing molecules on their surface, memory T cells can be 
divided into two subsets. CD62Llow CCR7(CC-chemokine receptor 7)low are defined 
as effector memory T cells, while CD62Lhi CCR7hi are defined as central memory T 
cells (46-48). 
Current evidence suggests that the survival of memory T cells is not dependent on 
persistent antigen. In fact, memory T cells are less dependent on antigen receptor 
engagement for survival than naive T cells. Instead, cytokines are important in 
maintaining memory T cell viability.  After pathogen and antigen are cleared in acute 
infection, memory CD8+ T cells are maintained by signals through receptors that 
contain the common cytokine receptor γ-chain such as receptors for IL-7 and IL-15. 
IL-7 and IL-15 appear to deliver survival and proliferative signals to memory CD8+ T 
cells, respectively (49;50).  
 
1-2-1 Clonal expansion  
Naive T cell activation needs both peptide–MHC complexes (signal 1), and co-
stimulatory signals (signal 2) (51;52). Moreover, activation of innate immune cells 
induces the production of pro-inflammatory cytokines, such as type I IFNs, IL-12  and 
IFNγ (53). Recent studies demonstrated that pro-inflammatory cytokines act directly 
on responding CD8+ T cells to affect crucial aspects of memory generation (signal 3). 
Early in vitro studies showed that the addition of IL-12 or type I IFNs to T-cell 
cultures enhanced the proliferation and survival of the activated T cells. These studies 
led to the concept that signal 3 was important for optimal CD8+ T-cell responses 
(54;55). T cells deficient in various cytokine receptors (for example, for type I IFNs, 
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IL-12 or IFNγ) have reduced expansion (56-58).  Importantly, the absence of these 
pro-inflammatory cytokine receptors does not compromise proliferation of these 
gene-deficient TCR-transgenic T cells; instead it decreases their survival rates (56-58). 
How these cytokines act on the survival of activated T cells is not clear yet, but it’s 
possible that they might increase the expression of pro-survival molecules such as 
Bcl-3 or potentially alter the balance of pro-apoptotic and anti-apoptotic Bcl-2-family 
members to promote T-cell survival during proliferation (54;59). 
 
1-2-2 Clonal contraction 
Following acute or persistent infection, activated T-cells go to clonal contraction 
through two apoptotic pathways, AICD and ACAD (60). 
Early in vitro studies showed that effector, but not memory CD8+ T cells exhibited 
heightened sensitivity to AICD through CD95 and TNF-mediated cell-death pathways 
(61;62), whereas in vivo studies showed normal contraction of CD8+ T cells that lack 
both of these molecules (63;64). Current studies show that the balance and activation 
state of pro- and anti-apoptotic Bcl-2 family members modulate the death of activated 
T cells (39;65-68). Deletion of Bim severely compromises the death of superantigen-
activated T cells in vivo (39) and results in reduced contraction of antigen-specific 
CD8+ T cells after herpesvirus infection (66). However, in Bim-deficient mice 
infected with LCMV, some antigen-specific CD8+ T-cells eventually contract. This 
suggests that additional pathways might contribute to the death of activated CD8+ T 
cells (14;69;70). 
  FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL      JIANNING MAO            18 
Inflammatory cytokines such as IFNγ and IL-12 can influence the contraction phase 
as well. CD8+ T cells failed to contract in BALB/c IFNγ-deficient mice after infection 
with an attenuated (actA-deficient) strain of L. monocytogenes that was otherwise 
cleared in wild-type and immunocompromised hosts (71). Also, BALB/c IFNγ-
deficient mice and B6 IFNγ-deficient mice have reduced contraction after LCMV 
infection (71;72). After infection with L. monocytogenes, both CD8+ and CD4+ T 
cells exhibit abnormal contraction in IFNγ-deficient or IFNγR-deficient mice that 
were treated with antibiotics to eliminate the infection at day 4. So, persistent 
infection does not explain how IFNγ regulates CD8+ and CD4+ T-cell contraction 
after infection with L. monocytogenes (73;74). IFNγ might act indirectly through cells 
other than T cells to influence CD8+ T-cell contraction (72;75). Finally, the absence 
of the IL-12 receptor on antigen-specific T cells not only reduced expansion but also 
reduced contraction after infection (76). So, pro-inflammatory cytokines contribute 
important signals to regulate the contraction phase, perhaps by regulating Bcl-2-
family members. 
Recent studies also suggested that pro-inflammatory signals, specifically IL-12, 
control the amount of T-bet expression in the responding CD8+ T cells (77). In this 
model, relative T-bet expression is thought to differentiate short-lived effector CD8+ 
T cells (T-bethi) from memory precursor effector CD8+ T cells (T-betlow) and thus 
determines the cell’s fate. However, T-bet-deficient TCR-transgenic CD8+ T cells 
from P14 mice still contract by more than 80% from the peak of the response 
following LCMV infection (77) and the LCMV-specific CD8+ T-cell response 
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appears to undergo normal contraction in T-bet-deficient mice (78). So the link 
between T-bet and the contraction of the CD8+ T-cell response is still not clear. 
How a precise fraction (5–10%) of the responding CD8+ T cells survives to initiate 
the memory pool is still not clear. Recent data demonstrate that naive CD8+ T cells 
undergo an initial asymmetric division after interaction with APCs (79). This raised 
the possibility that the segregation between long-term memory T cells versus short-
lived effector-T-cell may be a very early event in the CD8+ T-cell response.  
 
Many molecules are involved in T cell activation and apoptosis program. Through 
DNA microarray analysis of the mRNA expression profile of activation versus resting 
mouse T cells, we identified a group of differentially expressed genes, which are 
likely important in T-cell activation and apoptosis. Drak2 is a gene in this group. 
 
2. DAPK and Drak2 
 
2-1 Death-associated protein kinase (DAPK) 
Death-associated protein kinase (DAPK) is a Ca2+/calmodulin (CaM)-regulated 
Ser/Thr kinase that mediates cell death (80-84). Increased DAPK activity, due to 
overexpression of the kinase, leads to pronounced death-associated cellular changes, 
which include membrane blebbing, cell rounding, detachment from extracellular 
matrix, and the formation of autophagic vesicles. Furthermore, DAPK activity is 
necessary for the induction of cell death by multiple death signals, including those 
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generated by death receptors, cytokines, matrix detachment, and oncogene-induced 
hyperproliferation (80). 
DAPK belongs to a family of related death kinases, all of which share significant 
sequence and functional homology (85). This family consists of DAP (86) , DRP-
1(DAPk-related protein 1, also known as DAPk2) (87), ZIP kinase [also known as 
Dlk (DAP-like kinase) or DAPk3] (88), DAPK2 (89), Drak1 and Drak2 (DAPK-
related apoptosis-inducing protein kinase-1 and -2) (90)(Fig.5). Each DAPk family 
member contains at its N terminus a catalytic domain composed of the typical 11 
subdomains found in all Ser/Thr kinases (80). Phylogenetically, the DAPK family is 
most closely related to the family of CaM-regulated kinases, in particular to myosin 
light chain kinase, which shares 44% identity within the corresponding catalytic 
domain (83). Beyond the common kinase domain, the family members differ in 
structure. DAP, DRP-1 and DAPK2 have a calmodulin regulatory domain following 
the kinase domains, ZIP, Drak1 and Drak2 do not (85). This domain serves to 
suppress catalytic activity by binding to the catalytic cleft, and functions as a 
pseudosubstrate. In addition, this domain undergoes autophosphorylation at Ser308, 
an inhibitory event that reduces its affinity to CaM and may further stabilize its 
docking within the substrate-binding site (80). The C terminus of DAPk contains a 
death domain, followed by a 17-aa tail rich in Ser residues, a feature common to other 
death domain-containing proteins (87). The 52-kDa ZIPk possesses a C-terminal 
leucine zipper motif, which mediates homodimerization and interactions between 
ZIPk and additional leucine zipper-containing proteins, such as activating 
transcription factor (ATF)4 (88). 
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          Fig 5. Death-associated protein kinase (DAPK) family member: The numbers above the proteins 
demarcate the amino acid position of each domain. The quantities within the kinase domains indicate 
the degree of amino acid identity to the kinase domain of DAPk.  
 
2-2 DRAK2 
Drak2 shares about 50% identity in the kinase domain with other members of the 
DAPK family (86). DAP, DAPK2, and DRP-1 are localized in the cytosol, ZIP kinase 
and Drak1 reside mainly in the nuclei, whereas Drak2 is found in both the cytosol and 
nuclei (90;91), suggesting different mechanisms of action. An in vitro kinase assay 
revealed that both DRAKs are autophosphorylated and phosphorylate myosin light 
chain as an exogenous substrate (91). Furthermore, overexpression of both DRAKs 
induces the morphological changes of apoptosis in NIH 3T3 cells, suggesting the role 
of DRAKs in apoptotic signaling (90). CHP interacts with the carboxyl-terminal 
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region of the kinase domain of DRAK2 and specifically inactivates DRAK2 kinase 
activity (92).  
In Drak2−/− mice, Drak2−/− T cells did not demonstrate any defects in apoptosis or 
negative selection. However, T cells from Drak2−/− mice exhibited enhanced 
sensitivity to T cell receptor-mediated stimulation with a reduced requirement for 
costimulation. Drak2−/− mice were remarkably resistant to experimental autoimmune 
encephalomyelitis (EAE) (93). This study suggests that DRAK2 raises the threshold 
for T cell activation by negatively regulating signals through the TCR.  
However, our study (to be elaborated later) demonstrated that the conclusion based on 
Drak2-/- mouse study was flawed, due to the superficial investigation by McGargill et 
al. As a matter of fact, Drak2 is actively involved in T-cell apoptosis and memory T 
cell development (94).  
At the molecular level, apoptosis of T cells and other type of cells shares many 
common mechanisms. The important role of Drak2 in T-cell apoptosis led us to 
believe it is also essential in the survival of other type of cells, such as β-cells in the 
pancreatic islets, which are vital in maintaining normal blood glucose levels. 
Pathological changes in islets lead to diabetes. 
 
3. Diabetes  
Diabetes mellitus is one of the most common endocrine disorders in the world (Fig.6). 
Now, almost 6% of the world’s population is affected by this disease. And the number 
will reach 300 million in 2025, within them, 97% will be type 2 diabetes (95).  
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Fig 6. Numbers of people with diabetes (in millions) for 2000 and 2010 (top and middle values, 
respectively), and the percentage increase. 
 
There are two main forms of diabetes, type 1 and type 2. Both types are characterized 
by progressive ß-cell failure (Fig.7). Type 1 diabetes is caused by an autoimmune 
assault against the ß-cells (96), while the cause of type 2 diabetes is more variable, 
including environmental factors such as physical inactivity, obesity and genetic 
factors. Environmental factors can modify the expression of susceptible diabetes 
genes, and cause ß-cell failure and insulin resistance (96). 
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S97-107 
Fig 7. ß-cell death in T1D and T2D: Overview of the putative sequence of events leading to β-cell 
death in animal models of type 1 and type 2 diabetes.  
 
 
3-1 Type 1 diabetes 
In type 1 diabetes, β-cell mass is reduced by 70–80% at the time of diagnosis (97). 
Because of the variable degrees of insulitis and absence of detectable β-cell necrosis, 
it was suggested that β-cell loss occurs slowly over years. In antibody-positive 
individuals, progressive decline in first-phase insulin secretion, impaired fasting or 
glucose tolerance are usually found long before the development of overt diabetes 
(97). For patients with long-term type 1 diabetes, some β-cell function remains (C-
peptide secretion), although β-cell mass is usually decreased to less than 1% of 
normal (98).  
The β-cell loss is due to autoimmune attack. Typically in type 1 diabetes, 
autoantibodies reacting with glutamic acid decarboxylase (GAD65), insulin, and 
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insulinoma antigen-2 can be found (99). Some adults with type 2 diabetes also express 
anti-islet autoantibodies (most often GAD65 autoantibodies). These patients are called 
LADA (latent autoimmune diabetes of the adult). They have both insulin resistance as 
well as anti-islet autoimmunity. So type 1 and type 2 diabetes can coexist (100).  
β-cell death in the course of insulitis is caused by direct contact with activated 
macrophages and T-cells, and/or exposure to soluble mediators secreted by these cells, 
including cytokines, nitric oxide (NO), and oxygen free radicals (101). The execution 
of β-cell death occurs through activation of mitogen-activated protein kinases, ER 
stress and by the release of mitochondrial death signals (96). In vitro exposure of β-
cells to IL-1β, or to IL-1β + IFN-γ, causes functional changes similar to those 
observed in pre-diabetic patients, such as elevated proinsulin/insulin levels (102), and 
a preferential loss of first-phase insulin secretion in response to glucose. 
Apoptosis is the main cause of β-cell death at the onset of type 1 diabetes. It is a 
highly regulated process, which is activated and/or modified by extracellular signals, 
intracellular ATP levels, phosphorylation cascades, and expression of pro- and anti-
apoptotic genes (101). Cytokines induce stress response genes that are either 
protective or deleterious for β-cell survival. There are around 700 genes identified to 
be up- or downregulated in purified rat β-cells or insulin-producing cells after 1–24 
hour of exposure to IL-1β and/or IFN-γ by microarray experiments (Fig.8). IL-1β 
activates the transcription factor nuclear factor (NF)-κB in rodent and human islet 
cells (101), and IκB protects pancreatic β-cells against cytokine-induced apoptosis 
(103;104). NF-κB was also found to downregulate the expression of other 
transcription factors responsible for β-cell differentiation and function. NF-κB 
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regulates expression of inducible nitric oxide synthase (iNOS) in β-cells, and 50% of 
the ß-cell genes modified after 12 h of cytokine exposure are secondary to iNOS-
mediated NO formation. So IL-1β induced NF-κB activation plays a crucial role in 
controlling multiple and distinct gene regulatory networks in β cell. It affects the β-
cell differentiation and ER Ca2+ homeostasis, attracts and activates immune cells, and 
directly contributes to β-cell apoptosis.  
 
Cnop, M., Welsh, N., Jonas, J. C., Jorns, A., Lenzen, S., and Eizirik, D. L. (2005) Diabetes 54 Suppl 2, 
S97-107 
Fig 8. The transcription factor and gene networks putatively involved in the cytokine-promoted ß-cell 
"decision" to undergo apoptosis: The transcription factors NF-κB and STAT-1 are the main regulators 
of the pathways triggered by IL-1β and IFN-γ, respectively. 
 
 
However, exposure of purified human or rodent β-cells to IL-1β alone is not sufficient 
to induce apoptosis, but when IL-1β is combined with IFN-γ, 50% of these cells 
undergo apoptosis after 6–9 days (101). This suggests that IFN-γ signal transduction 
must synergize with IL-1β signaling to trigger β-cell apoptosis (Fig.9). IFN-γ binds to 
cell surface receptors and activates the tyrosine kinases JAK1 and JAK2. These 
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kinases phosphorylate the transcription factor STAT-1, which dimerizes and 
translocates to the nucleus to bind to γ-activated sites of diverse genes (101). STAT-1 
mediates the potentiating effect of IFN-γ on IL-1β–induced iNOS expression. 
Fluorescence-activated cell sorting (FACS)-purified β-cells from STAT-1–deficient 
mice (STAT-1–/–) are protected against IL-1β + IFN-γ–induced apoptosis. Because 
excessive activation of JAK/STAT signaling may lead to cell death, STAT 
transcriptional activity is regulated by multiple negative feedback mechanisms. These 
include dephosphorylation of JAK and cytokine receptors by SHP, and inhibition of 
JAK enzymatic activities by the suppressor of cytokine signaling (SOCS) family. 
Upregulation of SOCS-1 or SOCS-3 protects β-cells in vitro and in vivo against 
cytokine-induced death. SOCS-3 also protects insulin-producing cells against IL-1β–
mediated apoptosis via NF-κB inhibition. The results indicate that β-cell fate after 
cytokine exposure depends on the duration and severity of perturbation of key β-cell 
gene networks. NF-κB and STAT-1 play important roles in this network.  
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Cnop, M., Welsh, N., Jonas, J. C., Jorns, A., Lenzen, S., and Eizirik, D. L. (2005) Diabetes 54 Suppl 2, 
S97-107 
Fig 9. Cytokine-induced ß-cell apoptosis: Arrows indicate genes for which expression was modified by 
cytokines in a time course microarray analysis. β-Cell apoptosis is probably mediated by three main 
pathways—namely JNK, ER stress, and liberation of pro-apoptotic proteins from the mitochondria. 
 
 
Another question is to understand how the cytokine-activated gene expression results 
in β-cell death. The probable mechanisms include the following: 1) Fas/FasL pathway 
(105), 2) activation of the stress-activated protein kinases c-Jun NH2-terminal kinase 
(JNK), p38 mitogen-activated protein kinase (MAPK), and extracellular signal-
regulated kinase (ERK); 3) triggering of ER stress; and 4) the release of death signals 
from the mitochondria. 
Effector T cells induce apoptosis of β-cells. This then leads to absolute insulin 
deficiency and clinically manifest as diabetes, at least in the murine model of the 
autoimmune diabetes-NOD (nonobese diabetic) mice. T cell effector pathways 
involving Fas/Fas-ligand (Fas-FasL) interaction or the perforin/granzyme system are 
primarily responsible for the beta cell destruction. Perforin production from CD8+ T 
cells initiates the immune response, and then Fas/FasL interaction causes CD4+ T 
cell-induced beta cell death (100; 104).  
JNK is a member of the MAPK family. Pancreatic β-cells exposed to IL-1β have an 
early and sustained increase in JNK activity, which can be potentiated by IFN-γ or 
TNF-α (101;106). Cell-permeable peptide inhibitors of JNK prevent cytokine-induced 
apoptosis in insulin-producing cells (107), but this remains to be confirmed in primary 
β-cells. p38 MAPK and ERK are also activated by cytokines, and pharmacological 
inhibition of these MAPKs diminish cytokine-induced rat islet cell death (108;109), 
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probably by attenuating transcriptional activation of iNOS. In addition, the tumor 
suppressor p53 is activated in response to cytokine-induced NO production (110). It is 
conceivable that stabilization of the pro-apoptotic protein p53 lies downstream of the 
NO-induced activation of MAPKs.  
Disruption of ER homeostasis, as induced by changes in ER Ca2+ concentrations, 
triggers accumulation of unfolded proteins and activation of a specific stress response, 
which is called the ER stress response. This cellular response is a coordinated attempt 
to restore ER homeostasis and function, and it includes translational attenuation, 
upregulation of ER chaperones, and degradation of misfolded proteins. In prolonged 
and severe ER stress, the apoptosis program will be activated and executed by the 
transcription factor CHOP (C/EBP(CCAAT/enhancer binding protein) homologous 
protein), MAPK JNK, and caspase-12. Because of their high rate of protein synthesis, 
β-cells are particularly susceptible to ER stress (111). And NO induced ER stress 
response in β-cells leads to CHOP expression and apoptosis (112).  
Mitochondria play an important role in β-cell function and survival (113), as well as in 
triggering apoptosis. Members of the Bcl-2 protein family regulate the mitochondrial 
response to pro-apoptotic signals (114), preventing release of mitochondrial proteins 
such as cytochrome c. When cytochrome c is liberated to the cytosol, it will 
sequentially activate caspase-9 and -3 and execute cell death (115). Overexpression of 
Bcl-2 partially protects mouse (116) and human (117) islets against cytokine-induced 
cell death, but does not prevent adenovirus-induced islet cell death (118) or 
spontaneous diabetes in NOD mice (119). Caspase-1 is induced in β-cells exposed to 
IL-1ß + IFN-γ (120) , and blocking caspase-1 decreases β-cell apoptosis after 4 days 
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exposure to cytokine, but can not prevent their subsequent death by necrosis after 9 
days. These results suggest the possibility that during the early stage of cytokine 
exposure, nucleus, mitochondria, and ER could work togther to decide the fate of β-
cell to undergo apoptosis or not. Other pro-apoptotic genes that are induced by 
cytokines, as detected by microarray analysis (121), includes Bid, Bak, and caspase-3. 
 
3-2 Type 2 diabetes 
 
Modern lifestyle, with abundant nutrient supply and reduced physical activity, 
resulted in dramatic increases of type 2 diabetes (95). It occurs when the endocrine 
pancreas fails to secrete sufficient insulin to cope with the metabolic demand (122). 
Initially, reduced insulin sensitivity is the major problem, but at later stage, islet 
apoptosis also occurs (Fig.10). Three mechanisms are involved in type 2 diabetes: 1. 
Insulin risistance, 2. β-cell secretory dysfunction, 3. decreased β-cell mass. In type 2 
diabetic subjects, initial pathological studies suggested a β-cell loss of 25–50%. 
However, recent studies showed a significant reduction in β-cell mass and a threefold 
increase in β-cell apoptosis (122).  
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Kasuga, M. (2006) J.Clin.Invest 116, 1756-1760 
Fig 10. Development of type 2 diabetes: Insulin resistance associated with obesity is induced by 
adipokines, FFAs, and chronic inflammation in adipose tissue. Pancreatic β cells compensate for 
insulin resistance by hypersecretion of insulin. However, at some point, β cell compensation is followed 
by β cell failure, and diabetes ensues. 
 
3-2-1 Insulin resistance 
Changes in lifestyle, such as consumption of a high-calorie diet and lack of exercise, 
have increased the global prevalence not only of diabetes but also of obesity. Between 
60% and 90% of cases of type 2 diabetes now appear to be related to obesity. Insulin 
resistance, which is an impairment of insulin action that precedes the development of 
hyperglycemia is usually associated with obesity. It is therefore important to 
characterize the mechanisms of insulin resistance associated with obesity in order to 
develop approaches to prevent type 2 diabetes. 
3-2-1-1 Adipokines 
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Adipokines are a group of hormones and cytokines that are produced by adipocytes. 
Adipocytes can store excess lipids and this fuction becomes saturated in obesity, 
resulting in abnormal redistribution of lipids to other organs and tissues. In the ob/ob 
mouse, which exhibits hyperphagia, hyperlipidaemia and insulin resistance, the 
mutated gene is the cytokine-related molecule leptin (123). Leptin and adiponectin 
have been categorized as 'anti-diabetogenic'; their common function is to decrease 
triglyceride (TG) synthesis, stimulate β-oxidation and enhance insulin action in both 
skeletal muscle and liver. These effects can be explained in part by their common 
ability to activate 5'-AMP-activated protein kinase (AMPK) (124). This enzyme 
responds to a fall in ATP and a rise in AMP levels by activating both glucose and 
fatty acid oxidation. Interestingly, leptin levels are increased and adiponectin levels 
are decreased in insulin-resistant obese humans and animals, which suggests that 
obesity leads to a state of leptin resistance and adiponectin deficiency.  
Animals lacking white adipose tissue have severe hepatic and muscle insulin 
resistance, and exhibit large increases in TG stores in both tissues (125). This further 
proves the importance of adipose tissue in the normal regulation of insulin action. 
Transplantation of normal fat tissue into such mice restores insulin sensitivity (126). 
Leptin infusion ameliorates insulin resistance in these mice (127;128), while 
transplantation of fat from leptin-deficient mice into such animals fails to improve 
insulin sensitivity (129). These data suggest that leptin seems to be the major player in 
this model. Furthermore, leptin administration to humans with severe lipodystrophy 
partially reverses their insulin resistance and hyperlipidaemia (130).  
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Adipose cells also produce other peptide hormones, including adiponectin, retinol-
binding protein-4 (RBP4) and resistin, and proinflammatory cytokines such as IL-6 
and TNFα (124;131). 
Mice with an adipose-specific knockout of the Glucose transporter type 4 (GLUT4) 
have impaired insulin sensitivity in muscle and liver (132). Circulating RBP4 levels 
are increased in these mice, and infusion or transgenic expression of RBP4 in normal 
mice causes insulin resistance (133). Interestingly, food deprivation (fasting) also 
causes a form of insulin resistance and is associated with a decrease in adipose 
GLUT4 expression (134). So the original purpose of adipocyte-derived insulin-
desensitizing molecules, such as RBP4, TNFα and resistin, may have been to prevent 
hypoglycaemia in the fasted state, while in modern life style, with abundant nutrient 
supply, the function of these molecules has been subverted to pathophysiology (135). 
3-2-1-2 Inflammatory mediators 
Insulin resistance may also caused by inflammatory component (136). High-fat diets 
or obesity result in activation of the transcription factor NF-κB and its targets in the 
liver. Overexpression of a constitutively active version of the NF-κB-activating 
kinase, IκB kinase catalytic subunit-β (IκKβ), in the liver of normal rodents results in 
liver and muscle insulin resistance and diabetes. In addition, both high-fat feeding and 
IκKβ overexpression increase hepatic production of IL-6, IL-1β and TNFα; antibody-
mediated neutralization of IL-6 in animals fed on a high-fat diet partially restores 
insulin sensitivity (137). Deletion of IκKβ in the liver can protect mice from diet-
induced hepatic insulin resistance, while muscle and adipose insulin resistance still 
develop. However, myeloid cells specific IκKβ knockout mice remain globally 
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insulin sensitive (138). In rodents, after one week on high-fat feeding, adipocyte 
increases the expression of monocyte chemotactic protein-1 (MCP1), which recruits 
macrophage to adipocytes (139;140). This may be a mechanism by which 
inflammatory signalling is enhanced during the development of diabetes. Overall, 
evidence is accumulating that insulin resistance is at least partly caused by changes in 
hormone and cytokine production by the liver, adipose tissue and infiltrating immune 
cells in response to chronic exposure to lipids and other metabolic fuels. 
3-2-1-3 Metabolic overload in the liver 
Lipid species accumulation in the liver results in the redirection of long-chain acyl 
CoAs (LC-CoAs) into ER-localized and cytosolic lipid species, such as 
diacylglycerols (DAGs), ceramides and TGs. This is thought to be regulated mostly 
by glucose-induced increases of malonyl CoA. Malonyl CoA serves both as the 
immediate precursor of de novo lipogenesis and as an inhibitor of carnitine 
palmitoyltransferase-1 (CPT1), which is the rate-limiting enzyme for import of LC-
CoAs into the mitochondria for β-oxidation (141). Indeed, infusion of lipids or 
ingestion of high-fat diets in rodents leads to the accumulation of TGs, LC-CoAs, 
DAGs and ceramides (142-144). Suppression of mitochondrial glycerol-3-phosphate 
acyltransferase-1 (GPAT1, the first enzyme in TG synthesis) or acetyl CoA 
carboxylase-2 (ACC2) activity results in increased fatty acid oxidation, lowered DAG 
levels and reversal of hepatic insulin resistance (145-147). Pharmacological inhibition 
of Ser palmitoyltransferase-1 (SPT1) or genetic knockout of dihydroceramide 
desaturase-1 (Degs1) — both of which are involved in the synthesis of ceramides 
from the saturated precursor palmitoyl CoA — prevented hepatic insulin resistance 
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induced by glucocorticoid administration or infusion of saturated (but not unsaturated) 
fats in rodents (148). Finally, when obese patients with type 2 diabetes were fed on a 
hypocaloric low-fat diet, a modest weight loss (8 kg on average) was observed, but a 
reversal of hepatic insulin resistance was also seen in concert with a large decrease in 
intrahepatic, but not intramuscular, lipid deposits (149). 
3-2-1-4 Metabolic overload in muscle 
In muscle, intramuscular levels of lipid signalling molecules, such as LC-CoAs, DAG 
and ceramides, positively correlate with TG content and negatively correlate with 
insulin sensitivity (150;151). Pharmacological or genetic inhibition of ceramide 
biosynthesis in rodents attenuated muscle insulin resistance caused by infusion of 
high concentrations of palmitate (151), but not linoleic acid. This suggests discrete 
mechanisms for different fatty acids. Another study showed that transgenic 
overexpression of diacylglycerol acyltransferase-1 (DGAT1) in skeletal muscle 
increased TG content and prevented diet-induced insulin resistance, as well as reduce 
20–30% DAG and ceramide levels in muscle (152). However, muscle β-oxidation 
was not evaluated, and could have been reduced as a consequence of repartitioning 
lipids into esterification pathways. 
Recent work has suggested that mitochondrially derived by-products of lipid 
oxidation may have a key role in the development of insulin resistance in skeletal 
muscle (153). Chronic exposure of muscle to elevated lipids induces an increase in 
expression of genes of the fatty acid β-oxidative pathway (153;154). And the 
upregulation of the enzymatic machinery for β-oxidation in muscle is not coordinated 
with upregulation of downstream metabolic pathways, such as the tricarboxylic acid 
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(TCA) cycle and electron transport chain. This leads to incomplete metabolism of 
fatty acids and accumulation of lipid-derived metabolites in the mitochondria 
(153;154). Isolated mitochondria from insulin-resistant rat’s skeletal muscles have 
higher rates of incomplete fat oxidation compared with those from insulin-sensitive 
muscles (155). These abnormalities were reversed by exercise intervention in mice 
that were fed on a high-fat diet, in association with increased TCA cycle activity and 
restoration of insulin sensitivity and glucose tolerance. 
Other work has shown that obesity results in impaired switching from fatty acid to 
carbohydrate substrates during the fasting-to-fed transition and in a coincident 
reduction in levels of several TCA cycle intermediates (156). This phenomenon, 
known as metabolic inflexibility (157), was apparent at both the whole-body level and 
in isolated muscle mitochondria.  
3-2-1-5 Relating metabolic overload to insulin signalling 
Lipid-derived by-products such as DAG can regulate members of the protein kinase C 
(PKC) family. These kinases phosphorylate Ser on the insulin receptor and/or its 
immediate targets, insulin receptor substrate-1 (IRS1) and -2 (IRS2). In this way, they 
impair insulin-receptor-mediated Tyr phosphorylation of IRS1 and interfere with 
insulin signalling (158-161). Moreover, overexpression of GPAT1 in rat liver induces 
hepatic steatosis as well as increased hepatic DAG levels and activation of PKCε 
(162). While Gpat1-I knockout mice exhibit decreased PKCε activity and enhanced 
hepatic insulin sensitivity (163). Furthermore, silencing of hepatic PKCε in liver is 
sufficient to prevent hepatic insulin resistance caused by short-term high-fat feeding 
(164). 
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In skeletal muscle, PKCε is activated by lipid infusion in both humans and rodents, 
and PKCθ-knockout mice are protected from insulin resistance that is caused by acute 
lipid infusion (144). However, PKCθ is also required for the maintenance of normal 
skeletal muscle insulin sensitivity (165;166).  
Besides lipids, the concentrations of several amino acids are also elevated in obese 
patients with type 2 diabetes (167). And infusion of amino acids in rodent models or 
humans impairs skeletal muscle glucose uptake, increases hepatic gluconeogenesis 
and impairs insulin action (168-170). The machanism of amino acids on insulin 
signalling involves the activation of mTOR (mammalian target of rapamycin) and 
ribosomal protein S6 kinase-1 (S6K1). S6k1-knockout mice have increased insulin 
sensitivity and are protected against diet-induced insulin resistance. In modern 
lifestyle, the consumption of protein is also increased, so amino-acid-induced 
pathways might synergize with lipid-induced mechanisms to cause the full syndrome 
of obesity-associated impairment of insulin action. 
Excess lipids and other metabolic changes associated with overnutrition may trigger 
stress responses in the ER (171). ER stress activates JNKs, which phosphorylate IRS1, 
thereby interfering with insulin action.  
3-2-2 β-cell secretory dysfunction  
The two major mechanisms causing β-cell secretory dysfunction are glucotoxicity and 
lipotoxicity. 
3-2-2-1 Glucotoxicity 
Hyperglycemia reduces glucose-induced insulin secretion (GIIS) in β-cell, thereby 
contributing to the progression from glucose intolerance to overt type 2 diabetes (172). 
  FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL      JIANNING MAO            38 
Rodent β-cells chronically exposed to high glucose display several alterations of their 
phenotype, including changes in glucose stimulus-secretion coupling, gene expression, 
cell survival, and cell growth (173). These alterations could result from cytokine, 
oxidative stress, or ER stress–induced changes in gene expression and cell survival 
(174;175) or from functional changes such as accumulation of glycogen (176).  
The genes involved in GIIS in in vivo and in vitro models of prolonged exposure to 
high glucose include insulin, GLUT2, glucokinase and voltage-dependent Ca2+ 
channels, and the transcription factors that regulate their expression (177). These 
changes have some similarities with those happening under exposure of cytokines 
(178). On the other hand, several genes expressed at low levels in normal β-cells are 
induced by hyperglycemia, including hexokinase 1, lactate dehydrogenase and 
glucose-6 phosphatase. In addition, pro- and anti-apoptotic factors, antioxidant 
enzymes, and some transcription factors are upregulated. Some of these genes, such 
as c-Myc, A20, and heme-oxygenase 1, are induced by hyperglycemia as well as 
cytokines. Hyperglycemia might increase β-cell production of IL-1ß in human islets 
(106). Howerever, iNOS and IκBα, two NF-κB–dependent genes markedly induced 
by IL-1β, are not induced in rodent β-cells exposed to high glucose. Other genes, such 
as lactate dehydrogenase A, the mitochondrial uncoupling protein UCP-2, and the 
transcription factor CREM, are induced by hyperglycemia and downregulated by 
cytokines.  
3-2-2-2 Lipotoxicity 
Circulating adipose tissue–derived products, such as free fatty acid (FFA)s and 
adipokines, play a direct role in pancreatic ß-cell dysfunction and death. It is proved 
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that a high plasma concentration of FFAs is indeed a risk factor for the development 
of type 2 diabetes, independently of its effects on insulin sensitivity (179).  
Circulating FFAs are solubilized and transported in millimolar concentrations, 
because of their tight binding to albumin. Unbound FFA levels measure in the 
nanomolar range (5–20 nmol/l); at this concentration they are rapidly taken up via a 
protein-mediated transport. FFAs acutely stimulate insulin secretion, but prolonged β-
cell exposure to high FFA levels reduces GIIS in vitro (180) and in vivo, especially in 
individuals genetically predisposed to type 2 diabetes (181). Studies in the Zucker 
diabetic fatty (ZDF) rat, which is a type 2 diabetes model and has both insulin 
resistance and inadequate beta-cell compensation, indicate that high circulating FFAs 
and triglyceride levels induce triglyceride accumulation in pancreatic islets (182). The 
associated rise in cytoplasmic FFA levels would increase ceramide formation and 
induce iNOS, resulting in NO-mediated β-cell apoptosis (183).  
For in vitro experiments, physiological concentrations of palmitate and oleate are used 
to mimic the effect of FFA (96;184). FFAs are toxic to FACS-purified rat β-cells and 
insulin-producing INS-1E cells. Cytotoxicity depends on the unbound FFA 
concentration and palmitate has more effect than oleate. The toxic effects of FFAs are 
potentiated when β-cells are concomitantly exposed to high glucose levels (185;186). 
FFA-induced cell death occurred in the absence of iNOS expression or NO production, 
and it was not counteracted by antioxidant or free radical scavenging compounds, 
suggesting that oxidative stress is not its main mediator. Moreover, oleate or palmitate 
did not activate NF-κB in INS-1E or β-cells. FFA-induced cytoplasmic triglyceride 
accumulation was inversely correlated to β-cell death. A mixture of oleate and 
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palmitate caused the lowest cell death and the highest triglyceride accumulation, 
whereas bromopalmitate, which did not increase cellular triglycerides, exerted the 
highest toxicity (187). These findings suggest that storage of excess FFAs as 
triglycerides protects the cell against accumulation of potentially deleterious fatty 
acyl-CoA. 
FFA-induced β-cell toxicity might occur at the ER level, where FFA esterification 
takes place. Both oleate and palmitate caused alternative splicing of x-box binding 
protein-1 (XBP-1), activation of ATF6, and induction of the ER chaperone BiP in 
INS-1E cells. Besides these specific ER stress markers, ATF4 and CHOP are also 
activated. It is thus conceivable that a high FFA load, which exceeds the β-cell’s 
esterification capacity, impairs ER functions and triggers an ER stress response, thus 
contributing to β-cell toxicity. ER stress has been proposed as the cellular/molecular 
mechanism linking obesity with insulin resistance. So FFAs might be responsible for 
the ER stress response and impaired β-cell function observed in the hepatocytes and 
adipocytes of obese mice (188;189).  
3-2-3 Decreased β-cell mass 
Obese individuals who do not develop diabetes exhibit an increase in β-cell mass that 
appears to compensate for the increased metabolic load and obesity-associated insulin 
resistance. However, finaly this β-cell adaptation fails and the subset of obese 
individuals start to develop type 2 diabetes (122;190). 
Pancreatic ß-cell mass is regulated by at least four independent mechanisms: 1. β-cell 
replication, 2. β-cell size, 3. β-cell neogenesis, 4. β-cell apoptosis. 
3-2-3-1 Adaptation of β-cell mass to metabolic load 
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During adulthood, the β-cell mass is highly adaptive to changes in metabolic 
homeostasis. When obesity and the inherent insulin resistance occur in humans, β-cell 
mass first increase through an increase in β-cell replication and neogenesis, as well as 
β−cell hypertrophy (191). A small increase in β-cell apoptosis has also been observed 
in nondiabetic obesity; however, this is outweighed by increases in β-cell replication, 
neogenesis, and cell size, resulting in a net increase in β-cell mass. 
3-2-3-2 Failure of β-cell mass to compensate for metabolic load 
Although there is an initial compensatory increase in β-cell mass, the onset of type 2 
diabetes in both humans and rodent models is accompanied by a progressive decrease 
in β-cell mass. This β-cell loss arises from a marked increase in β-cell apoptosis, 
which far outweighs modest increases in β-cell replication and neogenesis (192). As 
the type 2 diabetic state progresses, the situation gets worse; the incidence of β-cell 
replication decreases and the β-cell population declines. In humans, the increased β-
cell apoptosis in type 2 diabetes is further exacerbated by the formation of amyloid 
plaque deposits in islets (193). Eventually, type 2 diabetes occurs and the patient must 
be treated with insulin replacement therapy. 
3-2-4 The role of IRS-2 signaling in β-cell survival and apoptosis 
Many mechanisms could trigger the increase in β-cell apoptosis that occurs during the 
pathogenesis of type 2 diabetes such as ER stress, chronic hyperglycemia, chronic 
hyperlipidemia, oxidative stress, and certain cytokines (122;190). 
IRS-2 is an especially potent pathway in promoting β-cell survival and dampening of 
IRS-2 signaling leads to insulin resistance as well as β-cell apoptosis (194) (Fig.11). 
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Fig 11. Insulin signaling in cells: Insulin elicits its effects by binding to its specific receptor and 
activating its tyrosine kinase. The activated insulin receptor kinase phosphorylates the intracellular 
substrate IRS, which then binds various signaling molecules containing the SH2 domain. Among them, 
the Grb2-Sos complex and SHP-2 transmit mitogenic signals through the activation of Ras. In contrast, 
PI3K (class IA) transmits the major metabolic actions of insulin via downstream effectors such as 
phosphoinositide-dependent kinase 1 (PDK1) and Akt. 
 
IRS protein family are intracellular tyrosine kinase substrates that act as signaling 
interfaces immediately downstream of cell surface receptors, such as the insulin and 
insulin-like growth factor-1 (IGF-1) receptors (173). Deletion of IRS-1 and IRS-2 
leads to marked insulin resistance, indicating that these genes play a key role in 
insulin action (195;196). Once an IRS molecule is tyrosine phosphorylated, certain 
signaling proteins dock to this specific IRS phosphotyrosine site by means of their 
SH2-domains, resulting in activation of downstream signaling pathways. For 
examples, phosphatidylinositol-3'-kinase (PI3'K)/protein kinase-B (PKB, also known 
as Akt) pathway and the Ras pathway that leads to activation of the MAP kinases Erk-
1 and Erk-2 (197). Both IRS-1 and IRS-2 are expressed in pancreatic β-cells. IRS-1 is 
not involved in the control of β-cell mass, but appears to function in cellular Ca2+ 
homeostasis (198). IRS-2 plays a critical role in regulation of β-cell growth (199). 
Increased IRS-2 expression can promote ß-cell replication, neogenesis, and survival 
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(194), whereas decreased IRS-2 expression causes spontaneous β-cell apoptosis (200). 
Thus, IRS-2 is critically important for maintaining β-cell mass, especially by 
promoting β-cell survival (194). So, mechanisms leading to suppression of IRS-2 
expression in β-cells may be linked to the increased incidence of β-cell apoptosis and 
the onset of type 2 diabetes. 
Tyrosine phosphorylation of IRS-2 leads to increased β-cell growth and survival 
(192). However, IRS-2 also contains multiple sites for serine/threonine 
phosphorylation, which, for the most part, have a negative effect on IRS signal 
transduction by promoting IRS degradation (201). Several mechanisms relevant to the 
pathogenesis of type-2 diabetes could potentially increase IRS-2 serine/threonine 
phosphorylation, subsequently resulting in IRS-2 ubiquitination, proteosomal 
degradation, and ultimately β-cell apoptosis.  
Chronic hyperglycemia can lead to chronic activation of mTOR in β cells. Activated 
mTOR triggers serine/threonine phosphorylation of IRS-2 and its subsequent 
proteosomal degradation, leading to increased β-cell apoptosis (202). Chronic 
hyperglycemia can also trigger β-cell apoptosis by additional mechanisms, such as 
"glucotoxicity." 
Hyperlipidemia also causes ß-cell apoptosis by lipotoxicity (203). Other lipotoxic 
mechanisms include the mitochondrial apoptotic pathway; inhibition of PKB (204); 
and fatty acid/ceramide–induced activation of the c-Jun N-terminal kinase (Jnk)/p38 
stress kinase pathway (205). Interestingly, Jnk/p38-mediated phosphorylation of IRS-
2 may also be induced by hyperglycemia, underscoring a likely interplay between 
glucotoxicity and lipotoxicity mechanisms in β-cell apoptosis (206).  
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IL-1β also plays a role in inducing β-cell apoptosis in type 2 diabetes (207). In 
obesity-linked diabetes, leptin, TNFα, and IL-6 are increased. Leptin has recently 
been shown to modulate IL-1β induced apoptosis in human β cells (208). Some of 
these cytokines can induce β-cell apoptosis through induction of signaling pathways 
that activate the transcription factor NF-κB (209). However, they may also activate 
signaling pathways that trigger increased degradation of IRS-2. Certain cytokines, 
such as leptin, IL-6, and IFN-γ, activate JAK/STAT. This leads to increased 
expression of SOCS-1 and SOCS-3 proteins, which normally bind to the leptin, IL-6, 
and IFN-γ receptors and inhibit JAK-2/STAT signaling. SOCS-1 and SOCS-3 have 
also been shown to bind to the C terminus of IRS molecules, leading to their 
ubiquitination   and subsequent degradation (210). Thus leptin and IL-6 may cause β-
cell apoptosis by decreasing β-cell IRS-2 levels through a similar mechanism. IL-1β 
and TNFα promote activation of the protein kinase IκK (106). IκK phosphorylates the 
cytosolic inhibitory protein IκB, resulting in release and activation of NF-κB (106). 
However, IκK has also been shown to phosphorylate IRS molecules on 
serine/threonine sites, promoting their degradation (211). In β cells, this could trigger 
apoptosis. In addition, IL-1β and TNFα are known to activate Jnk/p38 "stress protein 
kinases" as well PKCδ. Jnk/p38 and PKCδ may also increase the serine/threonine 
phosphorylation state of IRS-2, leading to IRS-2 degradation and ultimately β-cell 
apoptosis.  
 
 
4. Objectives of my work  
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Our DNA microarray data indicated that Drak2 was significantly modulated during T 
cell activation. We thus decided to investigate the role of this molecule in the immune 
system and then extended our study to its role in islet survival and diabetes. The 
objectives of our studies were as follows. 
1) To study the Drak2 expression pattern during ontogeny using in situ 
hybridization analysis; 
Previous publication on Drak2 failed to detect Drak2 expression outside the T-
cell compartment (93). We will employ in situ hybridization to identify 
localized Drak2 expression in organs and during embryonic development. 
2) To investigate the role of Drak2 in T-cell immune response, T-cell survival, 
and memory T-cell development; 
Drak2 belongs to DAP kinase family which is involved in apoptosis. So we 
will investigate the role of Drak2 in T cell apoptosis and immune response. 
3) To explore the role of Drak2 in islet β-cell survival and its role in type 1 and 
type 2 diabetes pathogenesis; 
Drak2 gene located close to type 1 and type 2 diabetes loci. This leads us to 
investigate the role of Drak2 in diabetes.  
4) To identify the substrate of Drak2 kinase.  
It’s known that Drak2 autophosphorylates itself, and phosphorylates myosin 
light chain as an exogenous substrate (90). Its endogenous substrates, other 
than itself, have not been identified. We decide to identify the substrate of 
Drak2 for the investigation of its signalling pathway. 
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ABSTRACT 
 
Drak2 is a death-associated protein (DAP) family serine threonine kinase. Its 
expression and roles in the immune system were investigated in this study.  According 
to in situ hybridization, Drak2 expression was ubiquitous at the mid-gestation stage in 
embryos, followed by more focal expression in various organs in the perinatal period 
and adulthood, notably in the thymus, spleen, lymph nodes, cerebellum, 
suprachiasmatic nuclei, pituitary, olfactory lobes, adrenal medulla, stomach, skin and 
testes. Its expression was high in resting T cells, but was downregulated after T cell 
activation. Drak2 transgenic (Tg) mice were generated using the human β-actin 
promoter. These Tg mice showed normal T- versus B-cell and CD4 versus CD8 
populations in the spleen, but their spleen weight cellularity was lower in comparison 
to wild type mice. After TCR activation, the proliferation response in Drak2 Tg T cells 
was normal, although their IL-2 and IL-4 but not IFN-γ production was augmented. 
Activated Drak2 Tg T cells demonstrated significantly enhanced apoptosis in the 
presence of exogenous IL-2. At the molecular level, Drak2 Tg T cells manifested a 
lower increase of anti-apoptotic factors during activation; such a change probably 
rendered the cells vulnerable to subsequent IL-2 insults. The compromised apoptosis in 
Drak2 Tg T cells was associated with reduced numbers of T cells with the memory cell 
phenotype (CD62Llo), and repressed secondary T-cell responses in delayed-type 
hypersensitivity. Our study demonstrates that Drak2 expresses in the T-cell 
compartment, but is not T-cell-specific; it plays critical roles in T-cell apoptosis and 
memory T-cell development.  
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INTRODUCTION 
 
To elucidate the molecular mechanisms of T-cell activation and differentiation, we 
conducted DNA microarray analysis employing the mouse 15,000 cDNA panel of the 
National Institute of Aging, USA, to compare gene expression patterns of resting versus 
activated T cells (anti-CD3 and anti-CD28 stimulation for 24 h). Drak2 was one of the genes 
found to undergo significant changes after activation, and was thus selected for further 
investigation. 
 
Drak2 is a serine/threonine kinase belonging to a family of death-associated protein kinases 
(DAP kinases), which consists of DAP (1), DRP-1 (2), ZIP kinase (3), DAPK2 (4), Drak1 
and Drak2 (5). Drak1 and Drak2 share 67.1% identy in their kinase domain and 24.2% 
identy in their non-catalytic regions (5). Drak2 also shares about 50% identity in the kinase 
domain with other members of the family (2). While DAP, DRP-1 and DAPK2 have a 
calmodulin regulatory domain in their C-terminal, ZIP, Drak1 and Drak2 do not (1-5). DAP, 
DAPK2, and DRP-1 are localized in the cytosol (1,2,4), ZIP kinase and Drak1 resides 
mainly in the nuclei (3,5), and Drak2 is found in both the cytosol and nuclei (5,6), 
suggesting different mechanisms of action. When DAP family kinases are overexpressed in 
various cells, apoptosis ensues, either directly, or after cytokine stimulation (1-5), indicating 
their involvement in apoptosis.  
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The mechanism of action and regulation of the prototype DAP family kinase, DAP, at the 
molecular level have been better studied. During apoptosis, DAP can associate with TNFα 
receptor and Fas-associated death domain, whereas in surviving cells, it binds to 14-3-3 (7). 
It phosphorylates myosin light chain II in vivo and is necessary for serum-induced stress 
fibre formation (8); it also phosphorylates p19arf and suppresses fibroblast oncogenic 
transformation (9). DAP is capable of autophosphorylation, which is inhibitory to its kinase 
activity (10). It also interacts with DAP-interacting protein-1, which is an E3 ubiquitin 
ligase and regulates the cellular level of DAP (11). Much less is known about the 
mechanisms of action of Drak2. It autophosphorylates and phosphorylates myosin light 
chains as an exogenous substrate (5), although its endogenous substrates have not been 
identified. Drak2 interacts with a calcineurin homologous protein (6), but the biological 
significance of this interaction is not clear. According to DNA microarray (12) and real-time 
reverse transcription/ polymerase chain reaction (RT-PCR) analysis (13) of different tissues, 
Drak2 is considered exclusively expressed in the T-cell compartment, yet such analyses are 
not precise, as these methods cannot reveal possible focal Drak2 expression in certain 
organs.  
 
The immune system of Drak2 null-mutant mice was investigated recently by McGargill et al. 
(13). Unexpectedly, in vitro, Drak2-/- T cells have no apparent defect in activation-induced 
apoptosis, after stimulation with anti-CD3 and anti-CD28; this leads to a conclusion by the 
authors that Drak2 does not play significant roles in T-cell apoptosis. Interestingly, Drak2-/- 
T cells have a lowered threshold to stimulation, compared to wild type (WT) T cells; the 
mechanism of such a phenomenon has not been explored. 
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In this study, we mapped the Drak2 expression pattern during ontogeny, and conducted a 
detailed in vitro and in vivo investigation of its functions in the immune system, using 
transgenic (Tg) mice with actin promoter-driven Drak2 expression. The novelty of our study 
is as follows. We corrected two misconceptions that Drak was expressed only in the T-cell 
compartment, and it did not involved T-cell apoptosis. We also provided evidence that 
Drak2 controlled T-cell memory response.  
 
MATERIALS AND METHODS 
 
In situ hybridization (ISH) 
A 1516-bp ApaI/KpnI mouse Drak2 cDNA fragment (positions 1150 to 2676) derived from 
MGC-6721 (American Type Culture Collection, Rockville, MD) was cloned in pCMV-
SPORT6, and was named pCMV-SPORT6-Drak2Δ, which was employed to generate sense 
and antisense riboprobes, using SP6 and T7 RNA polymerase for both 35S-UTP and 35S-CTP 
incorporation (14).  Tissues were frozen in -35°C isopentane, and kept at -80°C until cut.  
ISH was performed on 10-μm cryostat sections, as outlined previously (14). Anatomic ISH 
was conducted with X-ray films. ISH microscopy was undertaken with photographic 
emulsion followed by 8-day exposure. The slides were developed and then counter-stained 
with hematoxylin.  
Northern blot analysis 
A partial Drak2 cDNA fragment (clone H3022H03, National Institute of Aging, mouse 15K 
cDNA clone set; positions 17-2554, according to the sequence in GeneBank, accession 
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number NM_133810) was labelled with a digoxin (Dig)-labelling kit from Roche Applied 
Sciences (Laval, Quebec, Canada).  Total RNA was extracted from cultured cells with 
Trizol (Invitrogen, Burlington, Ontario, Canada). RNA (20 μg/lane) was resolved in 0.9% 
formaldehyde agarose gels, and transferred to N-Hybond nylon membranes (Amersham 
Biosciences, Baie d’Urfe, Quebec, Canada). The membranes were hybridized with Dig-
labelled probes, and the signals were revealed by a Dig detection kit (Roche Applied 
Sciences). Band intensities of 18S and 28S ribosome RNA were indicators of even RNA 
loading. 
 
Generation of Drak2 Tg mice 
Mouse full-length Drak2 cDNA (MGC-6721) was excised from the vector with  XbaI and 
SalI, and cloned into  XbaI and BamHI sites in vector pAC between the human β-actin 
promoter and β-actin polyA signals. The resulting construct was named pAC-Drak2. The 
4090-kb ClaI/ClaI fragment containing the β-actin promoter, Drak2 cDNA and β-actin 
polyA signal was excised and injected into fertilized C3HxC57BL/6 eggs. Genotyping of 
the Tg mice was first performed by Southern blot analysis. Tail DNA of the founders (10 
μg/each) was digested with PstI, and resolved by 1% agarose gel electrophoresis. The DNA 
was transferred onto N+ Hybond nylon membranes after denaturation. A 2-kb band specific 
to the transgene was detected by the same Dig-labelled Drak2 probe, as was employed in the 
Northern blot analysis. PCR was conducted for subsequent genotyping. The 5’ and 3’ 
primers were GCTAGGCTTCTGTTGGCTAGC and 
GAATGCAATTGTTGTTGGTAACTTG, respectively, to detect a 800-bp band. The 
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following PCR condition was employed: 940C x 2 min, 1 cycle; 940C x 16 sec, 600C x 1 min, 
720C x 1.5 min, 30 cycles; 720C x 5 min, 1 cycle.  
  
Real-time RT-PCR 
Drak2 mRNA in Tg and WT cells was measured by real-time RT-PCR; the 5’ and 3’ 
primers were CACAGCTGGCCACAGACTTC and CAGAGGACCTGAGAGTCAG, 
respectively. A 160-bp product was detected with the following amplification program: 
950C x 15 min, 1 cycle; 940C x 15 s, 550C x 30 s, 720C x 30 s, 40 cycles.  
 
Real-time RT-PCR was also conducted to assess Bcl-2, Bcl-xL and Flip mRNA levels. The 
5’ and 3’ primers for Bcl-2 were CTCGTCGCTACCGTCGTGACTTCG and 
GTGGCCCAGGTATGCACCCAG, respectively, for the detection of a 380-bp band; the 5’ 
and 3’ primers for Bcl-xL were TGGAGTAAACTGGGGTCGCATC and 
AGCCACAGTCATGCCCGTCAGG, respectively, for the detection of a 264-bp band; the 
5’ and 3’ primers for Flip were GTGGAAGAGTGTCTTGATGAAG and 
GAGCGAAGCCTGGAGAGTATT, respectively, for the detection of a 480-bp band. The 
amplification program was the same as that used for Drak2 mRNA.  
 
β-actin mRNA levels were measured as internal controls; the 5’ and 3’ primers were 
TGGTACCACAGGCATTGTGAT and TGATGTCACGCACGATTTCCCT, respectively, 
with the same amplification program as for Drak2 mRNA.  
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Real-time PCR was performed in triplicate, and the signal ratios of Drak2/β-actin, Bcl-2/β-
actin, Bcl-xL/β-actin and Flip/β-actin represented the normalized expression levels of these 
genes.  
 
Confocal microscopy 
Drak2 Tg and WT lymph node cells were placed on slides by Cytospin (Shandon, Pittsburgh, 
PA), stained with anti-Thy1.2-PE; the cells were subsequently fixed with 4% 
paraformaldehyde and permeablized with 0.2% Triton x-100. The slides were then stained 
with rabbit anti-Drak2 Ab (Abgent, San Diego, CA; 1:50 dilution) followed by FITC-
conjugated sheep anti-rabbit Ab (Chemicon, Temecula, CA). Such a staining procedure 
avoided possible failed binding of anti-Thy1.2 mAb to denatured Thy1.2, and prevented 
entry of anti-Thy1.2 mAb into cytoplasm as background fluorescence.  The cells were 
visualized under a Carl-Ziess confocal microscope, with excitation at 488 nm and emission 
at 505-550 nm for FITC, and with excitation at 543nm and emission at 560-615 nm for PE. 
The cell surface Thy1.2 is shown in red, and intracellular Drak2 is in green. 
 
Flow cytometry 
T cell, B cell, CD4 cell, and CD8 cell populations in the spleen were analysed by flow 
cytometry. CD25, CD69 and CD62L expression in T cells was investigated by gating on 
Thy1.2 cells, as described in our previous publication (15). Annexin-V staining was 
conducted in Thy1.2-gated T cells or transfected CTEV cells, according to a procedure 
described before (16).  
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T-cell lymphokine secretion and proliferation 
T cells were purified according to established methods (15). They were stimulated with solid 
phase anti-CD3, or solid phase anti-CD3 plus anti-CD28. In some experiments, total spleen 
cells were stimulated with mitomycin-C-treated BALB/c spleen cells in mixed lymphocyte 
culture. Cell supernatants were collected and assayed for IL-2, IFN-γ and IL-4 by ELISA. 
Proliferation of T cells and transfected CTEV cells was measured with 3H-thymidine uptake. 
All these methods have been detailed in our previous publication (15).  
 
Transfection of CTEV cells 
CTEV cells (17) were transfected with pCMV-SPORT6-Drak2 (MGC-6721) using 
Lipofectamine (Invitrogen) according to the manufacturer’s instructions; pCMV-SPORT6-
Drak2Δ, which contains the Drak2 3’ untranslated region served as a control. Twenty-four h 
after tranfection, dead cells were removed by Lympholyte-M gradient; test and control 
samples with similar viability of about 80% were cultured overnight, and stained with 
annexin V to assess cell apoptosis.  
 
The transfected cells were also selected with G-418 for 20 days. Then, a similar number of 
viable cells (4x105 cells/200 μl/well) from the test and control samples were cultured for 16 
h in the presence of 3H-thymidine, and harvested for the measurement of thymidine uptake.  
 
DTH assay  
Mice were first primed by painting their shaved abdominal skin with FITC. On day 6, ear 
thickness was measured, and then the ears were challenged by FITC painting. Ear thickness 
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was again measured after 24 h on day 7, and any increases were registered. This method has 
been described elsewhere (15). To assess the secondary DTH response, these mice were 
reprimed with FITC on the abdominal skin on day 21; on day 24, ears thickness was 
measured, and ears were rechallenged by FITC painting; ear thickness was quantified after 
24 h on day 25, and any increases were recorded.  
 
RESULTS 
 
Drak2 expression during ontogeny and lymphocyte activation 
Drak2 expression during ontogeny is not known. Its expression was studied previously with 
DNA microarray and with real-time RT-PCR in various tissues (12,13). The limitation of 
these methods is that they are not able to identify focal expression in a given organ. We, 
therefore, employed ISH to map the Drak2 expression pattern during ontogeny, starting 
from embryonic day 12 (e12), and in adult organs, using an antisense probe derived mainly 
from the Drak2 3’ untranslated region, which does not share significant homology with 
other members of the DAP kinase family.  
 
In the mid-gestation stage on e12 and e14, Drak2 presented ubiquitous expression in most 
organs (Figs. 1A and 1B). During the perinatal period on e18 and postnatal day 1 (p1), 
Drak2 expression diminished in most organs but was very high in the thymus (Figs. 1C and 
1D). Further expression modulation occurred after birth. On p10 (Fig. 1E) as well as in 
adulthood (Fig. 1F), Drak2 was prominently expressed in lymphoid organs, such as the 
thymus, spleen and lymph nodes; in addition, high-level signals were detected in the 
cerebellum (Cb), skin (Sk), intestine (Int),  testes (Tes) and vertebrae (Vb), which probably 
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reflected the signals from bone marrow. ISH of individual adult organs revealed that in the 
thymus, Drak2 signals were concentrated in the cortex, whereas in the spleen, in the white 
pulp (Fig. 2A-H). In the brain (Figs. 2I and 2J), olfactory lobe (OL), ventricular zone (VZ), 
hippocampal area CA1 (CA1), dentate gyrus (DG), cerebellum (Cb), and pituitary 
intermediate (IL) and anterior lobes (AL) presented  high-level expression. Most 
interestingly, the suprachiasmatic nuclei were positive for Drak2 mRNA, suggesting 
Drak2’s involvement in the circadian rhythm (Fig. 2K). Drak2 was also expressed in the 
adrenal gland medulla (Fig. 2L), non-glandular (N Gl) and glandular (Gl) regions of the 
stomach (Fig. M), and testes spermatocytes (Spc), Sertoli cells and Leydig cells (Fig. N). 
These results clearly demonstrate that Drak2 expression is not restricted to the T-cells 
compartment, and its expression in several brain regions, where no active apoptosis occurs, 
suggests that it has functions other than the regulation of apoptosis.  
 
Drak2 expression during T-cell activation was investigated by Northern blot analysis. 
Thymocytes and spleen T cells were stimulated with anti-CD3 (clone 2C11), and were 
harvested at 5 h and 24 h. As shown in Fig. 2O, two discrete bands representing differential 
splicing products of Drak2 above the 18S ribosome marker were detected in unstimulated 
cells; their intensity decreased after 5 h and 24 h, indicating downregulation after T-cell 
activation.  
 
Generation of Drak2 Tg mice 
Tg mice expressing human β-actin promoter-driven Drak2 were generated to study Drak2 in 
vivo function in the immune system. The plasmid construct for Tg mice generation is 
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illustrated in Figure 3A. Three Tg founders were identified by Southern blot analysis, which 
revealed 2-kb bands specific to Tg mice (lines 877 and 907 were shown in Fig. 3B). 
Increased Drak2 mRNA expression in mature spleen T cells was confirmed by real-time 
RT-PCR in line 887 Tg mice (Fig. 3C); similar data were obtained from line 907 (data not 
presented). Drak2 protein in line 907 Tg and WT lymph node T cells were verified by 
confocal microscopy employing rabbit anti-Drak2 Ab and anti-thy1.2 mAb double staining 
(Fig. 3D); Drak2 overexpression (in green) in nuclei and cytosol of Tg T cells (according to 
cell surface staining of Thy1.2, in red) was obvious compared to WT T cells, in which weak 
Drak2 signals (in green) were still detectable; control rabbit Ab did not stain the cells (data 
not shown).  
Lines 887 and 907 were expanded for detailed study. These mice were fertile and 
manifested no gross anomalies upon visual inspection except for their spleen weight. Both 
lines had a similar phenotype in vitro and in vivo. Therefore, in most of the cases, unless 
specified otherwise, representative data for line 887 are reported.  
 
Lymphokine production and proliferation of Drak2 Tg T cells 
 
Spleen weight and cellularity (Fig. 4A) were moderately but consistently reduced in 
Drak2 Tg mice. T- versus B-cell, and CD4- versus CD8-cell ratios in the spleen of Tg 
mice were comparable to those of WT controls (Figure 4B). Expression of the T-cell 
activation markers CD25 and CD69 was normal in Drak2 Tg T cells stimulated by anti-
CD3, anti-CD3 plus anti-CD28, or PMA plus ionomycin (Fig. 4C).  
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We next examined the cytokine production and proliferation of Tg T cells (Fig. 5). 
Compared to WT T cells, IL-2 and IL-4 but not IFN-γ secretion after anti-CD3 or anti-CD3 
plus anti-CD28 stimulation in Tg T cells was augmented (Fig. 5A). On the other hand, 
despite the augmented IL-2 and IL-4 secretion, Tg T-cell proliferation stimulated by anti-
CD3, anti-CD3 plus anti-CD28, or alloantigen was comparable to that of WT T cells, 
suggesting that IL-2 and IL-4 were not rate-limiting factors for proliferation. 
 
Enhanced apoptosis in activated Drak2 Tg T cells in the presence of exogenous 
IL-2 
 
Kinases of the DAP family, including Drak2, have been implicated in apoptosis of various 
cell types, despite a controversial report that Drak2-/- T cells do not seem to undergo 
abnormal apoptosis after TCR ligation (13). Using Drak2 Tg mice, we set out to examine 
Drak2’s effect on T-cell apoptosis, not only after simple TCR ligation, but also under the 
influence of IL-2, which is critical for activated T-cell apoptosis (18). WT and Drak2 spleen 
T cells were activated by solid-phase anti-CD3 and anti-CD28; 24 h later, exogenous IL-2 
was added; at 72 h, apoptosis was assessed by annexin V staining. As shown in Fig. 6A, 
without exogenous IL-2, WT and Tg T cells presented similar rates of apoptosis (37.6% 
versus 33.5%, first column). In the presence of exogenous IL-2, Tg T cells demonstrated a 
drastic increase of apoptosis over WT T cells (63.1% versus 27.6%, second column). 
Persistent TCR ligation is known to favour T-cell apoptosis; under physiological or 
pathophysiological conditions, TCR ligation is probably a lot shorter than 72 h. We 
wondered whether the survival of WT and Tg T cells in the presence of IL-2 was still 
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different if the TCR ligation duration was shortened. To this end, WT and Tg T cells were 
transferred to uncoated wells after 24-h stimulation with anti-CD3 and anti-CD28, and IL-2 
was then added as before. As illustrated in the third column (Fig. 6A), apoptosis was 
reduced in WT and Tg T cells compared to continuous T-cell ligation (column 2), as 
expected, but Tg T cells still had a much higher apoptosis rate than WT T cells (48.3% 
versus 17.5%).  
 
We next employed in vitro Drak2 transfection to confirm our findings on the proapoptotic 
role of Drak2 in Tg T cells. An IL-2-dependent T cell line CTEV (17) was transfected with a 
Drak2 expression construct, pSPORT6-Drak2 (MGC-6721, ATCC), in which full-length 
Drak2 cDNA was placed after a CMV promoter; the majority of dead cells were removed 
after 24 h with Lympholyte-M gradient. The remaining cells were of similar viability (about 
80%) in the test sample (transfected with pSPORT6-Drak2) and the control (transfected with 
pSPORT6-Drak2Δ). After an additional 16 h culture, cell apoptosis was measured with 
annexin V staining. Compared to cells transfected with the control construct, CTEV cells 
transiently transfected with pSPORT6-Drak2 showed significantly increased apoptosis, as 
measured by annexin V-positive percentage.   
 
We tried to establish stable pSPORT6-Drak2-transfected CTEV cells using standard G418 
selection. However, compared to cells transfected with the control construct, pSPORT6-
Drak2-transfected cells displayed a significantly slower proliferation rate according to visual 
inspection, and only a small amount of cells survived after a long-term selection process of 
about 20 days. These cells constantly had low viability according to trypan blue staining. On 
day 20 after transfection, an equal number of viable cells from the test and control samples 
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were pulsed with 3H-thymidine for 16 h, and thymidine uptake was measured to quantify 
their proliferation. As shown in Fig. 6B, indeed, pSPORT6-Drak2-transfected cells 
presented drastically reduced growth, most likely due to their high apoptosis rate. Thus, 
Drak2 overexpression led to augmented CTEV cell apoptosis.  It is to be emphasized that in 
this CTEV cell model, IL-2 was always present, and this model was quite similar to that of 
Fig. 6A, in which enhanced apoptosis was observed in activated Tg T cells in the presence 
of IL-2. 
To understand the molecular mechanisms of T-cell apoptosis associated with Drak2 
overexpression, we surveyed the expression levels of a group of anti-apoptotic factors in Tg 
versus WT T cells. Bcl-2, Bcl-xL and Flip were expressed at low levels in resting WT and 
Tg T cells, and were significantly induced 24 h after activation in WT T cells (Fig. 6C); 
however, such induction was compromised in Tg T cells. In the following 24 h (i.e., from 24 
h to 48 h after the initiation of culture), in the presence or absence of IL-2, the difference 
between WT and Tg T cells was not apparent in terms of Bcl-2, Bcl-xL and Flip expression, 
although Tg T cells underwent augmented apoptosis in the presence of IL-2 at 72 h. The 
data suggest that the compromised elevation of these anti-apoptotic factors in activated Tg T 
cells at an early stage within 24 h of activation rendered the T cells vulnerable to subsequent 
high-concentration IL-2 insults. The results of this section demonstrate that Drak2 regulates 
T-cell apoptosis; such an effect is revealed in the presence of higher IL-2 concentration.  
Compromised in vivo T-cell memory responses in Drak2 Tg mice 
After T-cell clonal expansion in an immune response, IL-2-dependent apoptosis is 
implicated in the efficacy of memory T-cell development (18). The high apoptosis rate in 
activated Drak2 Tg T cells in the presence of exogenous IL-2 raised the possibility that 
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memory T-cell development in these mice might be compromised. Indeed, in middle-aged 
Tg mice (7 months old), T cells with CD62Llo expression, one of the memory T-cell 
phenotypes, were increased in percentage, compared to WT mice (Fig. 7A), whereas such a 
phenotype was not apparent in young Tg mice (3 months old, data not shown). Using T-cell 
dependent DTH, we assessed memory T-cell development functionally in Drak2 Tg mice. In 
the primary response measured one week after the first FITC skin priming, Drak2 Tg and 
WT mice exhibited similar ear thickness increment; however, Tg mice displayed 
significantly reduced secondary DTH responses (Fig. 7B). These data suggest that memory 
of the T-cell-mediated immune response is impaired in Drak2 Tg mice.  
 
DISCUSSION 
 
In this study, we investigated the role of Drak2 in mature T-cell apoptosis and memory T-
cell development. Several issues are worth discussing. 
 
We have corrected a misconception that Drak2 expression is T-cell-specific. Two previous 
publications using DNA microarray and RT-PCR failed to detect Drak2 expression outside 
the T-cell compartment (12,13). The limitation of those methods is that they could not 
identify localized gene expression in organs; moreover, Drak2 expression during embryonic 
development was not studied before. Employing ISH, we found that Drak2 was ubiquitously 
expressed during the mid-gestation stage, around e12 and e14, indicating the participation of 
this gene in embryonic development. Drak2-/- mice presented no gross anomalies in their 
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development (13), but this could have been due to the overlapping and rescuing functions of 
other DAP family kinases.  Later, in adult mice, Drak2 expression became more restricted 
with high levels in the thymus, spleen and lymph nodes; however, many other regions and 
organs, such as the OL, VZ CA1, IL, AL, SCh in the brain, the Gl and N Gl in the stomach, 
the adrenal medulla, skin, and testes also showed prominent Drak2 expression, suggesting 
its broad functions outside the immune system. Drak2 expression in the central nerve system 
indicates that this molecule has important roles not related to apoptosis, which do not occur 
significantly in a normal brain. Drak2 expression in the SCh is especially intriguing, as this 
region is essential in controlling the behavioural circadian rhythm (19); Drak2 is one of a 
limited number of genes (excluding house keeping genes) with strong expression in the SCh. 
We monitored the Tg mouse circadian rhythm in 12-h dark/ 12-h light cycles according to 
their wheel-running activity (20), but abnormalities was not found, compared to WT mice. It 
would be very interesting to examine whether Drak2-/- mice have an impaired circadian 
rhythm. The Drak2 gene expression pattern revealed by in situ hybridization provides a 
useful guidance for further exploration of Drak2 functions in different organs. Actin 
promoter-driven Drak2 Tg mice were generated for such explorations; however, in this 
paper, our attention was focus on the role of Drak2 in mature T cells.  
 
Two previous publications failed to discover a role of Drak2 in T-cell apoptosis (13, 21). 
We have proven that Drak2 served a critical function in T-cell apoptosis, but such an effect 
was only obvious in the presence of exogenous IL-2. IL-2 is not only a critical lymphokine 
for T-cell activation, but, paradoxically, it is also essential in activated T-cell apoptosis, as 
first reported by Lenardo in 1991 (18). Physiologically, IL-2-dependent T-cell apoptosis 
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could be important in clonal shrinkage after clonal expansion during an immune response, 
and high in vivo IL-2 concentration could be achieved locally in the vicinity of activated T 
cells either as an autocrine or paracrine; consequently, the degree of such apoptosis will 
decide the pool size of surviving T cells, which further differentiate into memory T cells. 
This could be one of the explanations for the severe autoimmune diseases in mice deficient 
in IL-2 production (IL-2 gene null mutant) or IL-2 signal reception (IL-2 receptor β gene 
null mutant) (22,23). Indeed, we have found that secondary but not primary T-cell DTH 
responses were diminished in Drak2 Tg mice, and middle-aged Drak2 Tg mice had elevated 
CD62Llo populations; all these observations are consistent with the notion that Drak2 
influences memory T-cell development, which was compromised in the presence of Drak2 
overexpression. It is noteworthy that Drak2 expression was normally downregulated 24 h 
after T-cell activation (Fig. 2O), after a surge within 90 min (21).  Although the meaning of 
the rapid surge is not clear, the down regulation after 24 h probably represents a mechanism 
to prevent excess apoptosis of activated T cells by raising their threshold of vulnerability 
towards IL-2, and allowing some of the activated T cells to survive and develop into 
memory cells. Taken together, our data suggest that Drak2 is essential in regulating memory 
T-cell development. 
 
How Drak2 affects apoptosis is now currently known. We observed that Drak2 Tg T cells 
had intrinsic defects in upregulation of anti-apoptotic factors, such as Bcl-2, Bcl-xL and Flip, 
24 h after activation, although at that time point before addition IL-2, Tg and Wt T cells had 
not difference in their survival rates. This suggests that Drak2 renders T cells susceptible to 
IL-2-induced apoptosis induction by reducing their protection by anti-apoptotic factors. 
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Further studies will be required to elucidate the links between Drak2 and diminished 
apoptotic factor expression. 
 
In adult Drak2 Tg mice, there was a small but consistent reduction of spleen weight and 
cellularity, which might reflect compromised ongoing secondary immune responses to 
environmental antigens. Excessive T cell apoptosis likely contributes to such an anomaly; 
whether this also involves abnormal B cells apoptosis is currently under investigation.  
 
In summary, our study suggests that Drak2 plays critical roles in mature T-cell apoptosis 
and memory T-cell development, and this molecule also has functions related and unrelated 
to apoptosis in a variety of organs. One of its mechanisms in inducing T-cell apoptosis is to 
downregulate anti-apoptotic factors, which makes the cells vulnerable to apoptotic insults.  
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FIGURE LEGNEDS 
Figure 1. Drak2 expression during ontogeny according to in situ 
hybridization
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X-ray autoradiography (dark field) of Drak2 in situ hybridization in mice from e12 to 
adulthood, as indicated, is shown (A-F, right column). Hybridization with the sense 
probe (S) is presented as controls in the left column (A’-F’). Abbreviations are as 
follows: CNS, central nervous system; SpC, spinal cord; Th, thymus;  BM, bone 
marrow; Cb, cerebellum; H, heart; K, kidney; Int, intestine; Li, liver; Lu, lung; Sk, 
skin; SMax, submaxillary gland; Spl, spleen; St, stomach. Bar = 1 cm. Ages are 
indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL                  NING MAO     90 
 
 
 
Figure 2. Drak2 expression in selected adult tissues 
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A-N: In situ hybridization of selected adult tissues for Drak2 expression 
Hybridization with the sense probe (S) on various tissues (B and D, thymus; F and H, 
spleen) is included as negative controls.  A-D: thymus (Me, medulla; Cx, cortex); E-H: 
spleen (WP, white pulp; RP, red pulp); I: brain (OL, olfactory lobe; VZ, ventricular 
zone; CA1, hippocampal area CA1; DG, dentate gyrus; Cb, cerebellum); J: pituitary 
gland (AL, anterior lobe; IL, intermediate lobe; PL, posterior lobe); K. Brain 
suprachiasmatic nuclei and vicinity (V III, third ventricle; SCh, suprachasmiatic 
nuclei); L: adrenal gland (long arrow, medulla; short arrow, cortex); M: stomach (N 
Gl, non-glandular region; Gl, glandular region); N: testis (large arrows, Sertoli cells; 
thin arrows, interstitial Leydig cells; Sp, spermatocytes). Panels A, B, E, F, and I-M 
are dark field X-ray autoradiography; panels C, D, G, H, and N are bright field 
emulsion autoradiography with hematoxylin counterstaining.  
O: Northern blot analysis of Drak2 expression 
Thymocytes and spleen T cells were activated by soluble anti-CD3 (0.1 μg/ml, right 
panel). The duration of activation is indicated. Bands of 28S and 18S ribosomal RNA 
are presented to show RNA loading.  
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Figure 3. Generation and characterization of Drak2 Tg mice 
 
A. pAC-Drak2 construct for Drak2 Tg  mice generation  
The 4.9-kb ClaI/ClaI fragment was used for microinjection.  
B. Southern blot genotyping of Drak2 founder tail DNA  
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The 2.0-kb band specific to the Drak2 transgene is indicated.   
C. Real-time RT-PCR of Drak2 mRNA from spleen T  cells 
 
Means +  SD of ratios of Drak2 versus β-actin signals are shown; samples are in 
triplicate. 
D. Immunofluorescent staining of Drak2 in WT versus Tg T cells.  
Permeablized lymph node T cells were double-stained with rabbit anti-Drak2/sheep 
anti-rabbit Ig-FITC and anti-Thy1.2-PE mAb, and signals were registered by 
confocal microscopy. Cell surface Thy1.2 is shown in red, and intracellular Drak2 is 
in green. 
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Figure 4. Characterization of Drak2 Tg lymphoid organs and cells 
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A. Spleen  weight and cellularity in Drak2 Tg  mice   
Ten pairs of Tg mice and their WT littermates were compared for their spleen weight 
and cellularity. The difference was highly significant (p=0.0003 for weight, and 
p=0.01 for cellularity, paired Student’s t test). 
B. Spleen cell subpopulations for Drak2 Tg  mice  
T-cell (CD3+) and B-cell (B220+) populations, and CD4 and CD8 T-cell populations 
in Drak2 Tg and WT spleens were analyzed by 2-color flow cytometry. The 
percentages are indicated in the histograms. 
C. C69 and CD25 expression on activated Drak2 Tg T cells 
Drak2 Tg and WT T cells were stimulated overnight by solid phase anti-CD3 (4 
μg/ml), or anti-CD3 plus anti-CD28 (0.57 μg/ml and 2.86 μg/ml, respectively) 
(concentration used during coating). CD69 and CD25 expression on Thy-1.2-gated T 
cells was measured by 2-color flow cytometry (CD69/Thy1.2 and CD25/Thy1.2).   
The experiments described in Figures 4B and 4C were repeated more than 3 times, 
and representative data are shown.  
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Figure 5. Lymphokine production and proliferation of Drak2 Tg T cells  
 
Drak2 Tg and WT spleen T cells were stimulated by solid phase anti-CD3 (4 μg/ml), 
or solid phase anti-CD3 (0.57 μg/ml) plus anti-CD28 (2.86 μg/ml) (concentrations 
used during plate coating) as indicated. In mixed lymphocyte culture, total spleen 
cells from Drak2 Tg or WT mice were stimulated by mitomycin C-treated allogeneic 
BALB/c spleen cells. Supernatants were harvested on the days indicated, and assayed 
for lymphokines by ELISA (Fig. 5A). 3H-thymidine uptake of the remaining cells was 
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measured in triplicate (Fig. 5B). The experiments were repeated more than 3 times, 
and representative data with means + SD are shown.  
 
Figure 6. Drak2 T cells are prone to apoptosis  
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A. Augmented apoptosis of activated Drak2 Tg T cells in the presence of exogenous 
IL-2 
Drak2 Tg and WT spleen T cells were stimulated with solid phase anti-CD3 plus anti-
CD28, as described in Fig. 5, in the absence (first column) or presence (second 
column) of exogenous IL-2 (50 U/ml), which was added to the culture at 24 h. Some 
T cells (third column) were transferred from anti-CD3- and anti-CD28-coated wells to 
uncoated wells at 24 h, and exogenous IL-2 was then added to the culture. The cells 
were harvested at 72 h, and their annexin V expression was assessed by flow 
cytometry. 
B. Increased apoptosis and reduced proliferation of Drak2-transfected CTEV cells 
IL-2-dependent CTEV T cell line was transfected with pSPORT-Drak2 or a control 
construct pSPORT-Drak2Δ. After overnight culture, dead cells were removed by 
Lympholyte-M gradient, Test and control samples of similar viability (80%) were 
cultured for an additional 16 h, and their apoptosis was assessed by annexin V 
staining (right panel). The transfected cells were also selected by G418 for 20 days; 
then, a similar number of viable cells (according to trypan blue staining) from test and 
control samples (4x105/200 μg/well) were pulsed with 3H-thymidine for 16 h for the 
measurement of thymidine uptake (right panel). 
C. Compromised anti-apoptotic factor upregulation in activated Drak2 Tg T cells  
Drak2 and WT spleen T cells were activated by solid phase anti-CD3 and anti-CD28 
as described in Fig. 5. The cells were harvested, and their Bcl-2, Bcl-xL and Flip 
mRNA was measured by real-time RT-PCR. The samples were in triplicate, and 
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means + SD of the ratios of signals of these molecules versus those of β-actin are 
shown.  
All experiments were conducted more than 3 times, and data from representative 
experiments are shown. 
Figure 7. In vivo cellular and humoral immune responses of Drak2 Tg 
mice  
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A. Increased CD62Llo T-cell population in middle-aged Drak2 mice 
Peripheral blood T cells from Drak2 Tg or WT mice (6-8 months old) were double-
stained with Thy-1.2-PE and CD62L-FITC. The histograms showed CD62L 
expression on Thy1.2-gated cells; percentages of CD62Llo populations are indicated. 
Four pairs of Tg and WT mice were examined, and data from a representative pair are 
presented.  
B. Normal primary but compromised secondary DTH responses in Drak2 Tg mice 
Drak2 transgenic mice (total n=9; n=5 for line 887, and n=4 for line 907) and their 
WT littermates (total n=10; n=6 for line 887, and n=4 for line 907) were primed by 
FITC painting on abdominal skin on day 0, and challenged by FITC painting of the 
ear on day 6. Primary DTH was determined on day 7 by measuring the increase of ear 
thickness. The mice was reprimed on day 21 on abdominal skin, and rechallenged on 
the ear on day 24. Secondary DTH was measured on day 25 according to the increase 
of ear thickness. The increase in ear thickness of each mouse is presented. The 
difference between the 2 groups is not significant in their primary response (p=0.96), 
but highly significant (p<0.01, 2-tailed Student’s t test) in their secondary response. 
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ABSTRACT 
 
Drak2 is a serine threonine kinase in the death-associated protein family. In this 
study, we investigated its role in free fatty acid (FFA)-induced islet apoptosis. 
Drak2 mRNA and protein were rapidly induced in islet β-cells after FFA 
stimulation. Such Drak2 upregulation was accompanied by increased β-cell 
apoptosis, which was inhibited by Drak2 knockdown using siRNA. Conversely, 
transgenic (Tg) Drak2 overexpression led to aggravated β-cell apoptosis triggered 
by FFA. Drak2 overexpression in islets compromised the increase of anti-apoptotic 
factors, such as Bcl-2, Bcl-xL and Flip, upon FFA assault. Further in vivo 
experiments demonstrated that Drak2 Tg mice presented compromised glucose 
tolerance in a diet-induced obesity model. Our data show that Drak2 is 
detrimental to islet survival in the presence of excessive lipid. 
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INTRODUCTION 
 
Due to calorie-rich diet and sedative life-style, obesity is epidemic in industrialized 
countries. Taking the US as an example, 30% of its population are obese and 50% are 
overweight (1) Obesity favours the development of the metabolic syndrome, of which 
type 2 diabetes (T2D) is one manifestation. In T2D, reduced insulin sensitivity is the 
major problem (2) initially, but at a later stage, islet apoptosis is also involved. 
Blood free fatty acids (FFA) are generated mainly from lipolysis occurring in adipose 
tissues (3). They are the main energy source for non-glucose dependent tissues such as 
the liver, heart and muscles. In obesity, the blood FFA level is permanently increased 
(3), and such increase causes insulin resistance in the liver and skeleton muscles. This is 
then set the condition for the T2D development. The chronic elevation of blood FFA, 
especially saturated FFA such as palmitate has been shown to cause β-cell endoplasmic 
reticulum stress and apoptosis (4).  
Recent research has also revealed that adipose and other tissues in T2D release harmful 
inflammatory cytokines, which are detrimental to islet function and survival (5). In the 
late stage of T2D, increased blood glucose in combination of elevated FFA contribute 
to β-cell apoptosis (6).  
It is, therefore, conceivable that genes controlling β-cell apoptosis and survival are 
important in determining susceptibility to islet destruction and T2D risks. 
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Drak2 is a serine/threonine kinase belonging to a family of death-associated protein 
kinases (DAP kinases), which consists of DAP (7), DRP-1 (8), ZIP kinase (9), DAPK2 
(10), Drak1 and Drak2 (11). Drak2 shares about 50% identity in the kinase domain with 
other members of the family (7). While DAP, DRP-1 and DAPK2 have a calmodulin 
regulatory domain in their C-terminal, ZIP, Drak1 and Drak2 do not (7-11). DAP, 
DAPK2, and DRP-1 are localized in the cytosol (7,8,10), ZIP kinase and Drak1 reside 
mainly in the nuclei (9,11), whereas Drak2 is found in both the cytosol and nuclei 
(11,12), suggesting different mechanisms of action. Drak2 autophosphorylates itself, 
and phosphorylates myosin light chain as an exogenous substrate (11). Its endogenous 
substrates, other than itself, have not been identified. Drak2 interacts with a calcineurin 
homologous protein (12), but the biological significance of this interaction is not clear.  
When DAP family kinases are overexpressed in various cells, apoptosis ensues (7-11), 
indicating their involvement in apoptosis. In Drak2 transgenic (Tg) mice, Tg T cells 
manifest augmented apoptosis after TCR stimulation followed by culture in the 
presence of IL-2; as a consequence, the memory T-cell pool is diminished, and the Tg 
mice incur compromised secondary but not primary in vivo T-cell responses (13).  
In this study, we discovered that Drak2 expression in islets was rapidly induced by FFA. 
The induction was accompanied by islet apoptosis. Truncation of such Drak2 
upregulation protected β-cells from apoptosis thus induced. Drak2 overexpression in Tg 
islets resulted in increased β-cell death in vitro upon FFA stimulation, and Drak2 Tg 
mice developed glucose intolerance after diet-induced obesity. The implications of 
these findings are discussed.  
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MATERIALS AND METHODS 
 
Islet purification 
Islet purification is performed as we described before (14,15). Briefly, 2-ml of digestion 
solution (Hanks' balanced salt solution [HBSS] containing 20 mM HEPES and 2 mg/ml 
collagenase IV (Worthington Biochemical, Lakewood, NJ) were injected into the 
common bile duct of Tg or wild type (WT) mice (20-24 g) after the distal end of the 
duct was ligated. The distended pancreas was isolated and put into a 15-ml tube 
containing an additional 0.5 ml of digestion solution. The pancreas was digested at 
370C for exactly 28 min, and the digestion process was stopped by the addition of 10 ml 
of cold HBSS containing 20 mM HEPES. The islet suspension was filtered through No. 
7880 cheesecloth gauze (Tyco Healthcare, Mansfield, MA) and centrifuged at 500g for 
1-2 min. The pellet was washed with cold HBSS once at 500g for 1-2 min, and the 
supernatant was removed completely. The pellet was then resuspended in 3 ml of 25% 
Ficoll, and 2-ml layers of 23, 20, and 11% Ficoll were added sequentially. The Ficoll 
gradient was centrifuged at 700g for 5 min. Most of the islets were in the interface 
between the 20 and 23% Ficoll layers and were handpicked with Pasteur pipettes. They 
were then washed twice with cold HBSS. The islets were cultured overnight in RPMI 
1640 containing 10% FCS, and then used for experimentation. 
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Real time RT-PCR 
Drak2 mRNA in Tg and WT cells was measured by real-time RT-PCR; the 5’ and 3’ 
primers were CACAGCTGGCCACAGACTTC and CAGAGGACCTGAGAGTCAG, 
respectively. A 160-bp product was detected with the following amplification program: 
950C x 15 min, 1 cycle; 940C x 15 s, 550C x 30 s, 720C x 30 s, 40 cycles.  
 
Real-time RT-PCR was also conducted to assess Bcl-2, Bcl-xL and Flip mRNA levels. 
The 5’ and 3’ primers for Bcl-2 were CTCGTCGCTACCGTCGTGACTTCG and 
GTGGCCCAGGTATGCACCCAG, respectively, for the detection of a 380-bp band; 
the 5’ and 3’ primers for Bcl-xL were TGGAGTAAACTGGGGTCGCATC and 
AGCCACAGTCATGCCCGTCAGG, respectively, for the detection of a 264-bp band; 
the 5’ and 3’ primers for Flip were GTGGAAGAGTGTCTTGATGAAG and 
GAGCGAAGCCTGGAGAGTATT, respectively, for the detection of a 480-bp band. 
The amplification program was the same as that used for Drak2 mRNA.  
 
β-actin mRNA levels were measured as internal controls; the 5’ and 3’ primers were 
TGGTACCACAGGCATTGTGAT and TGATGTCACGCACGATTTCCCT, 
respectively, with the same amplification program as for Drak2 mRNA.  
 
Real-time PCR was performed in triplicate, and the signal ratios of Drak2/β-actin, Bcl-
2/β-actin, Bcl-xL/β-actin and Flip/β-actin represented the normalized expression levels 
of these genes.  
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Flow cytometry 
Drak2 Tg and WT islets were digested with 0.05% trypsin-EDTA to obtain single cell 
suspensions. The cells were fixed with 4% paraformaldehyde and permeabilized with 
0.2% Triton X-100. They were stained with rabbit anti-Drak2 Ab (Abgent, San Diego, 
CA; 1:50 dilution) and anti-insulin mAb (Sigma, St. Louis, MO; 1:500 dilution). 
Subsequently, they were stained with FITC-conjugated sheep anti-rabbit antibody 
(Chemicon, Temecula, CA), and PE-conjugated goat anti-mouse antibody (Jackson 
Immunoresearch, West Grove, PA), and analyzed by 2-color flow cytometry. Dispersed 
islet cells or small interfering RNA (siRNA)-transfected NIT-1 cells were also analyzed 
for apoptosis by flow cytometry using FITC-annexin V staining (16). 
 
Drak2 knockdown by siRNA in NIT-1 cells  
NIT-1 cells, derived from mouse insulinoma, were transfected with siRNA using 
Lipofectamine 2000 (Invitrogen, Burlington, Ontario) according to the manufacturer's 
instructions. For Drak2 siRNA, the oligonucleotide RNA sequences were 
CAUCCCUGAAGAUGGCAGCtt and GCUGCCAUCUUCAGGGAUGtt. The control 
was the scrambled sequence of said siRNA with following sequences: 
5'CCCUAAGUGUAGGACGCACtt and 3'GUGCGUCCUACACUUAGGGtt. Single 
stranded RNA pairs were annealed by being incubated for 1 min at 900C, and then 
cooled down to room temperature over 45 min. The final concentration of double-
stranded siRNA was 20 μM for transfection. 
 
Insulin release assay 
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After 48 h culture in complete F-12K medium with 10% FCS in the absence or 
presence of various stimulants, the islets were transferred to 12-well plates at a density 
of 10 islets/well. The islets were gently washed twice with 1 ml Kreb’s buffer (NaCl, 
135 mM; KCl, 3.6 mM; NaH2PO4, 5 mM; MgCl2, 0.5 mM; CaCl2, 1.5 mM; NaHCO3, 2 
mM; HEPES, pH 7.4, 10 mM; BSA, 0.07%), and then incubated in Kreb’s buffer 
containing 2.8 mM glucose for 5 min at 370C. Two hundred micro litres of supernatant 
were removed for determination of basal insulin levels. The islets were cultured for 
additional 40 min, and all the supernatants were harvested for determination of insulin 
levels as 2.8 mM glucose-stimulated release. The islets were then cultured in Kreb’s 
buffer containing 16.7 mM glucose for 45 min at 37 0C, and the supernatants were 
harvested for determination of insulin levels as 16.7 mM glucose-stimulated release. 
The insulin was assayed by ELISA (Linco Research, St. Charles, MO). The basal 
insulin levels, which were near zero, were deducted from the 2.8 mM and 16.7 mM 
glucose-stimulated levels in final data presentation, which was the fold increase of 
insulin levels of high glucose versus low glucose stimulation. 
Glucose tolerance tests 
Tg and WT mice were fed a high-fat diet (45% of total calories in the form of fat; 
Research Diets Inc. New Brunswick, NJ) from age 9 weeks for 6 weeks. They were 
then fasted for 16 h and injected i.p. with D-glucose (2 mg/g body weight) in PBS. 
Blood samples from the tail vein were taken at 15, 30, 60, 90, and 120 min after 
injection for glucose measurements with a glucose meter (Bayer, Toronto, Ontario). 
 
FFA measurements 
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Serum samples were collected and stored at −20°C until analysis. Their FFA 
concentrations were determined utilizing the nonesterified fatty acid assay kit (Wako, 
Richmond, VA) following a modified version of the manufacturer's protocol to 
accommodate a 96-well microplate. This method utilizes the acylation of coenzyme A 
by fatty acids in the presence of added acyl-CoA synthetase. Briefly, reagents A and B 
were prepared as directed by the protocol and then diluted with 13.3 ml of 0.05 M 
phosphate buffer. Seven standards, ranging from 0 to 1 mEq/L, were prepared from the 
supplied stock (1 mEq/L). The samples, standards, controls, and blanks were then 
added to a 96-well microplate in duplicate (10 μl/well). At that time, 100 μl of reagent 
A was added to each well and mixed prior to a 30-min incubation at room temperature. 
Finally, reagent B was added (200 μl per well), and mixed followed by an additional 
30-min incubation at room temperature, after which the plate was read at 550 nm. 
Utilizing the standard curve, sample values were expressed as mEq/L. 
 
RESULTS 
 
Rapid induction of Drak2 expression in islet β-cells and its association with islet 
apoptosis 
In obesity and T2D, high serum lipid is known to jeopardize islet function and survival 
(17). When isolated islets were exposed to FFA in vitro, Drak2 mRNA was drastically 
induced within 24 h (Fig. 1A). When FFA was injected into mice i.p., within 1 hour, 
serum FFA levels were increased (Fig. 1B). Such a FFA concentration increase was 
accompanied by a significant augmentation of Drak2 expression at 1 h (Fig. 1A; time 
shown was the duration between FFA injection and mouse sacrifice; the time of islet 
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isolation was not calculated in). The in vivo response was much faster than in vitro 
response. A likely explanation was that β-cells in vivo in the pancreas were in their 
natural environment with full viability and function, while isolated islets in vitro had 
experienced traumatic isolation procedures, and were slow to respond to additional 
stimuli.  
 
We next assessed Drak2 protein levels in β-cells, employing anti-insulin mAb and anti-
Drak2 Ab in 2-color flow cytometry. When the islets were stimulated with FFA, Drak2 
protein levels in insulin-positive β-cells were significantly augmented at 48h after FFA 
assault, as shown in histogram 1C; a summary of 3 independent experiments is 
illustrated in Fig. 1D. The finding on Drak2 protein increase was consistent with the 
heightened Drak2 mRNA expression at 24h. FFA induced islet cell apoptosis (Fig. 2A, 
top row, WT islets). Taken together, our data indicate that Drak2 overexpression in 
islets leads to their apoptosis.  
 
Drak2 knockdown by siRNA protected NIT-1 insulinoma cells from FFA-triggered 
apoptosis  
To prove that Drak2 was indeed critical to FFA-induced β-cell apoptosis, we employed 
siRNA to prevent Drak2 upregulation in NIT-1 insulinoma cells. NIT-1 cells were 
derived from a transgenic NOD mouse harbouring a hybrid rat insulin-promoter/SV40 
large T-antigen gene (18). As shown in Fig. 3A, similarly to normal β−cells, Drak2 
protein was induced in NIT-1 cells by FFA according to flow cytometry. Two different 
Drak2 siRNAs (#592 and #1162) significantly truncated Drak2 protein upregulation 
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stimulated by FFA, but a control siRNA had no effect on the Drak2 level. As in normal 
islet cells, FFA induced NIT-1 cell apoptosis after 24 h (Fig. 3B). However, with 
protection by the 2 Drak2 siRNAs #592 and #1162, but not the control siRNA, such 
apoptosis induction was truncated. We noticed that FFA-induced apoptosis in NIT-1 
cells occurred at 24 h after the FFA assault, compared with 48 h needed for normal islet 
cells. The faster apoptosis kinetics in NIT-1 cells was probably due to that they were 
transformed cells with more active cellular machinery for live and death decisions.  
 
Drak2 overexpression in Tg islets aggravated FFA-triggered apoptosis  
To further validate the role of Drak2 in islet survival, actin promoter-driven Drak2 Tg 
mice, as described in our previous publication (13), were studied. These mice are viable, 
fertile, and have no gross anomalies. They had comparable body weight with WT 
littermates from 6 wks to 22 wks old (Fig. 4A). Their serum inflammatory cytokine IL-
6 levels were similarly low as that of WT mice (Fig. 4B). There was no significant 
difference in fasting blood glucose levels between Tg and WT mice (Fig. 4C). We 
demonstrated in Fig. 4D that Drak2 protein expression in insulin-positive Tg islet cells 
was augmented both in terms of Drak2 mean fluorescent intensity (MFI) and 
percentage of Drak2 positive cells, compared with WT islet cells (MFI 22.1 in Tg β-
cells versus MFI 13.3 in WT β-cells; 97.2% versus 74.4% Drak2 positive Tg β-cells 
versus WT β-cells), according to Drak2/insulin two-colour flow cytometry.   
 
When Tg islets were stimulated with FFA for 24 h, their apoptosis was significantly 
increased, compared to WT islets (41.8% versus 20.2%; Fig. 2A, 2nd column). At 48 h, 
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WT islets also started to suffer from apoptosis, but Tg islets were inflicted with more 
damage (57.6% versus 42.2%, Tg versus WT; Fig. 2A, 3rd column; a summary of 3 
independent experiments with data collected at 48 h is illustrated in Fig. 2B). 
 
To assess the function of β-cells under FFA assault, we evaluated islet insulin release 
after 16.7 mM glucose stimulation. At 48 h after FFA assault, insulin released by the 
Tg β-cells was significantly lower than by WT β-cells (Fig. 2C). This confirmed that 
augmented Drak2 expression was harmful to β-cell function.  
 
Drak2 overexpression compromised anti-apoptotic molecule induction  
To understand the molecular mechanisms of β-cell apoptosis associated with Drak2 
overexpression, we surveyed the expression levels of a group of anti-apoptotic factors 
in Tg versus WT β-cells. Anti-apoptotic factors Bcl-2, Bcl-xL and Flip were expressed 
at low levels in WT and Tg β-cells, but were significantly induced 24 h after FFA 
stimulation in WT β-cells (Fig. 5); however, such induction was compromised in Tg β-
cells. The data indicate that Drak2 overexpression in islets reduce the elevation of anti-
apoptotic factors upon detrimental stimulation, and suggests that such compromise 
might be one of the reasons that renders β-cells prone apoptotic. 
 
Drak2 overexpression led to glucose intolerance in mice under high fat diet 
With a regular diet, Tg mice in the C57BL/6 background at 9 weeks of age had a 
moderate elevation of serum FFA, compared with WT mice, although the difference did 
not reach statistical significance (Fig. 6A). The Tg mouse serum fasting insulin level at 
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this stage was significantly higher than that of WT (Fig. 6B), probably due to insulin 
resistance caused by the higher serum FFA levels; such FFA-related insulin resistance 
and the subsequence insulin level increase has been reported previously (19). When the 
mice were fed a high fat-diet for 6 weeks to mimic a pre-T2D condition, i.e., diet-
induced obesity (20), both Tg and WT animals became overweight, on average 10 g 
heavier than mice on a normal diet (data not shown). After the high-fat diet, both 
groups maintained normal fasting blood glucose levels (Fig. 6C). However, Tg mouse 
serum FFA levels were significantly higher than those of WT mice (Fig. 6A); Tg mouse 
fasting insulin levels were significantly lower than those of WT mice. Moreover, in the 
glucose tolerance test, Tg mice manifested statistically significantly higher blood 
glucose levels at 30, 60 and 90 min after glucose injection (Fig. 6C). The interpretation 
of these results is given in the section of Discussion.  
DISCUSSION 
In this study, we have demonstrated that Drak2 is critical in β-cell apoptosis triggered 
by FFA. Further in vivo experiments proved that enhanced Drak2 expression reduced 
glucose tolerance after high-fat diet. It seems that Drak2 is in the pathway downstream 
of harmful signals received by islets upon FFA stimulation. 
 
We showed that Drak2 was upregulated in islet β-cells upon FFA stimulation, and such 
upregulation was correlated to decreased islet function and survival. Interestingly, 
although Tg islets had higher Drak2 expression, such over expression by itself did not 
manifest harmful effects on the islets, as Tg mice did not develop diabetes, and Tg 
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islets culture in medium did not suffer from increased apoptosis, compared to WT islets, 
until an exogenous detrimental factor FFA was present. This suggests that Drak2 might 
act on a two-hit mode, in which signalling event(s) (hit 1) derived from FFA 
stimulation as well as Drak2 (hit 2) are both required to results in β-cell damage and/or 
dysfunction. For normal islets, high Drak2 expression (hit 2) could be a consequence of 
FFA (hit 1). We hypothesize that in individuals with abnormally high basal Drak2 
expression in islets, less hit 1 might be sufficient to cause excessive islet damage or 
dysfunction, and thus these individuals are more prone to T2D development when 
facing increased serum lipid.  In humans, Drak2 gene is located in 2q33.2, and is 14.8 
Mbp away from a type 2 diabetes  risk region at 2q32.1 
(http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?cmd=entry&id=601724). An 
epidemiological study on T2D prevalence in individuals having enhanced Drak2 
expression will answer the question whether Drak2 is a bona fide diabetes risk gene in 
humans.  
 
We found Tg mice had a moderately increased serum FFA level compared with WT 
mice under a normal diet. The mechanism of such an increase is not clear at the present 
time. It is quite likely that such a FFA increase caused insulin resistance, which in turn 
was responsible for the elevated serum insulin levels. It was somewhat surprising that 
after a high-fat diet, in the presence of prolonged higher serum FFA levels in Tg mice, 
the fasting insulin levels of Tg mice were significantly lower than those of WT mice. A 
possible explanation is that the prolonged high FFA levels in Tg mice compromised 
islet β-cells in terms of insulin release and/or survival. When these mice underwent the 
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glucose tolerance test, they could not cope with the transient surge of blood glucose by 
providing sufficient insulin, and manifested a prolonged high glucose levels, compared 
to WT mice.  
 
Currently, our knowledge about the Drak2 activation pathway and Drak2 substrates is 
limited. We only know that Drak2 is a genuine substrate of itself. Obviously, genes in 
the Drak2 pathway could all be involved in FFA-induced islet dysfunction and 
apoptosis, which are critical factors in type 2 diabetes development. 
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FIGURE LEGNEDS 
Figure 1. Drak2 was rapidly augmented in islets treated with FFA 
 
A. Drak2 mRNA expression according to real time RT-PCR  
Islets were stimulated by FFA (0.7 mM oleate and palmitate mixed in a 2:1 ratio) in vitro, or 
C57BL/6 mice were injected with 15mM FFA 0.5ml (oleate and palmitate mixed in a 2:1 ratio) 
i.v. in PBS at the indicated time before sacrifice of the mice. For the in vivo experiment, the time 
indicated was from the time of FFA injection until the sacrifice; the duration of islet isolation 
(about 1 h) was not calculated in. Drak2 mRNA expression in islet cells was measured by real 
time RT-PCR. The ratio of Drak2 mRNA and β-actin mRNA was taken as a measure of Drak2 
mRNA levels. The samples were in triplicate, and the means + SD of 4-6 independent 
experiments (as indicated) are shown.  
B. Plasma FFA levels after FFA injection 
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C57BL/6 mice were injected i.p. with 0.5 ml of 15mM FFA (oleate and palmitate mixed in a 2:1 
ratio), and their plasma FFA levels 1 h after the injection were measured by ELISA. Samples 
were in duplicate. Means + SD of the injected and control groups are shown (n=4 for each 
group). The difference is statistically significant (p<0.01, Student’s t test). 
C.  and D. Drak2 protein expression according to flow cytometry 
C57BL/6 islets were cultured for 48 h in the absence or presence of FFA as described in Fig. 1A. 
The islets were dispersed after the culture and analyzed by 2-color flow cytometry for 
intracellular insulin and Drak2 staining. The experiment was repeated 4 times. A representative 
set of histograms is shown in Fig. 1B and the summary of all 4 experiments is illustrated in Fig. 
1C. The asterisk indicates a p value of  <0.01 according to Student’s t test. 
Figure 2. Drak2 Tg islets were prone to apoptosis upon FFA stimulation 
 
A and B. Flow cytometry analysis of islet cell apoptosis 
 FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL                           JIANNING MAO            122 
Drak2 Tg and WT islets were cultured in RPMI 1640 with 10% FCS and stimulated with FFA as 
described in Fig. 1. After 24 h or 48 h, as indicated, the islets were dispersed and analyzed by 
flow cytometry with annexin V staining. The percentage of annexin V-positive cells is shown in 
the histograms (Fig. 2A). The experiment was repeated 3-6 times and the mean + SD of data at 
48 h of all these experiments are illustrated in Fig. 2B. The asterisk indicates p<0.05, according 
to Student’s t test. 
 
C. Islet insulin release after FFA stimulation  
Islets from Tg or WT mice were cultured in F-12K medium with 10% FCS in the presence or 
absence of FFA as described in Fig. 1. Insulin release by these cells was conducted after 48 h. 
For each treatment, the fold increase between low glucose and high glucose stimuli was  
presented. Insulin release by Tg islets after FFA stimulation was significantly lower than that by 
WT islets (p<0.05, Student’s t test). 
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Figure 3. Drak2 siRNA inhibited Drak2 protein upregulation and reduced apoptosis in NIT-1 
cells upon FFA stimulation 
 
A. Drak2 protein levels in NIT-1 cells  
NIT-1 cells were transfected with 2 Drak2 siRNAs (#592 and #1162), or a control siRNA, which 
is with a scrambled sequence of #1162. The cells were cultured for 24 h in the absence or 
presence of FFA, as indicated, and then analyzed for intracellular Drak2 protein levels by flow 
cytometry. The experiment was repeated 4-5 times, as indicated, and means + SD of these 
experiments are shown. 
 
B. Drak2 siRNA prevented FFA-induced apoptosis in NIT-1 cells 
NIT-1 cells were transfected with 2 different Drak2 siRNAs (#592 and #1162), or a control 
siRNA, as described in Fig. 3A. The cells were cultured for 24 h in the absence or presence of 
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FFA, as indicated, and analyzed for apoptosis by flow cytometry with annexin V staining. The 
experiment was repeated 4-5 times, as indicated, and means + SD of percentage apoptosis of all 
of these experiments are shown. 
 
Figure 4. Features of Drak2 Tg mice 
 
A. Body weight of Tg and WT mice  
The body weight (means + SD) of Tg and WT littermates (n=4 for each group) from 6 wks to 22 
wks of age are illustrated. No significant difference in any time point is found (p>0.05, Student’s 
t test). 
 
B. Serum IL-6 levels of Tg and WT mice 
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Serum IL6 of Tg and WT mice (n=4 for each group) were measured by ELISA. The ELISA 
samples were in duplicate. Means + SD of IL-6 levels are shown. There is no statistical 
difference between the two groups (p>0.05, Student’s t test).  
C. Fasting serum glucose levels of Tg and WT mice 
Blood glucose of Tg and WT mice (n=4 for each group) were measured after overnight fasting. 
Means + SD of the glucose levels are shown. There is no statistical difference in the blood 
glucose levels of the two groups (p>0.05, Student’s t test).  
D. Drak2 overexpression in Tg β-cells 
Drak2 Tg or WT islets were analyzed by 2-color flow cytometry for Drak2 and insulin 
expression (right column). The percentage of Drak2 positive cells among insulin-positive cells 
and their mean fluorescent intensity (MFI) are indicated in the left column. Upper row, WT; 
bottom row, Drak2 Tg. 
 
Figure 5. Compromised anti-apoptotic factor upregulation in Drak2 Tg islets  
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Drak2 and WT islets were stimulated by FFA as described in Fig. 1. The islets were harvested 
after 24 h, and their Bcl-2, Bcl-xL and Flip mRNA was measured by real-time RT-PCR. The 
samples were in triplicate. Means + SD of the ratios of signals of these molecules versus those of 
β-actin from 2 independent experiments are shown.  
 
Figure 6. Features of Drak2Tg mice after diet-induced obesity 
 
A. Serum FFA levels of Tg and WT mice before and after high-fat diet 
Tg and WT mouse serum FFA levels were measured by ELISA before and after a 6-wk high-fat 
diet (HFD). The ELISA samples were in duplicate. Means + SD of the FFA levels of the two 
groups (n=4 for each group) are shown. The serum FFA levels of the Tg and WT groups were 
significantly different after HFD (p<0.05, Student’s t test). 
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B. Fasting serum insulin levels of Tg and WT mice before and after high-fat diet 
Tg and WT mouse fasting serum insulin levels were measured by ELISA before and after 6-wk 
HFD. The ELISA samples were in duplicate. Means + SD of the insulin levels of the two groups 
(n=4 for each group) are shown. The insulin levels of the Tg mice were significantly higher than 
those of WT mice before HFD, and were significantly lower than those of WT mice after HFD 
(p<0.05 in both cases, Student’s t test). 
 
C. Reduced glucose tolerance in Drak2 Tg mice after diet-induced obesity 
Drak2 Tg and WT mice were fed a high-fat diet for 6 weeks from 9 weeks of age. Both groups 
became obese at age 15 weeks when the glucose tolerance test was conducted. Tg mice on a 
high-fat diet presented significantly higher blood glucose at 30, 60, and 90 min after i.p. glucose 
injection, compared to WT mice (n=6 pairs, p<0.05, Student’s t test). 
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ABSTRACT 
 
Drak2 is a member of the death-associated protein family and a serine threonine kinase. In 
this study, we investigated its role in β-cell survival and diabetes. Drak2 mRNA and protein 
were rapidly induced in islet β-cells after stimulation by inflammatory lymphokines known 
to be present in type 1 diabetes. Drak2 upregulation was accompanied by increased β-cell 
apoptosis. β-cell apoptosis caused by the said stimuli was inhibited by Drak2 knockdown 
using siRNA. Conversely, transgenic (Tg) Drak2 overexpression led to aggravated β-cell 
apoptosis triggered by the stimuli. Further in vivo experiments demonstrated that Drak2 
overexpressed in Tg islets was responsible for a diabetes-prone phenotype. We established 
that inducible nitric oxide synthase was upstream and caspase-9 was down stream of Drak2 
in its signalling pathway. Purified Drak2 could phosphorylate ribosomal protein S6 (p70S6) 
kinase in an in vitro kinase assay. Drak2 overexpression in NIT-1 cells led to enhanced 
p70S6 kinase phosphorylation, while Drak2 knockdown in these cells reduced it. These 
mechanistic studies proved that p70S6 kinase was a bona fide Drak2 substrate. 
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INTRODUCTION 
 
Diabetes is a metabolic disorder in which pancreatic islets fail to produce sufficient insulin to 
prevent blood glucose from rising beyond a normal range. Type 1 diabetes is an autoimmune 
disease normally starting at a young age. In type 1 diabetes, insufficient insulin production is 
caused by the destruction of islets by T cells either directly or indirectly by inflammatory 
cytokines, such as IFNγ and/or TNFα plus IL-β (1, 2). It is conceivable that genes controlling 
islet apoptosis and survival are important in determining susceptibility to islet destruction, and, 
consequently, in determining diabetes risk as well as its onset tempo (3). Such genes can, 
therefore, be characterized as type 1 diabetes risk genes.  
Drak2 is a serine/threonine kinase belonging to a family of death-associated protein kinases 
(DAP kinases), which consists of DAP (4) , DRP-1 (5), ZIP kinase (6), DAPK2 (7), Drak1 and 
Drak2 (8). Drak2 shares about 50% identity in the kinase domain with other members of the 
family (4). While DAP, DRP-1 and DAPK2 have a calmodulin regulatory domain in their C-
terminal, ZIP, Drak1 and Drak2 do not (4, 5, 6, 7, 8). DAP, DAPK2, and DRP-1 are localized in 
the cytosol (4, 5, 7), ZIP kinase and Drak1 reside mainly in the nuclei (6, 8),  whereas Drak2 is 
found in both the cytosol and nuclei (8, 9), suggesting different mechanisms of action. Drak2 
autophosphorylates itself, and phosphorylates myosin light chain as an exogenous substrate (8). 
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Its endogenous substrates, other than itself, have not been identified. Drak2 interacts with a 
calcineurin homologous protein (4), but the biological significance of this interaction is not clear.  
 
Our in situ hybridization analysis has revealed that Drak2 expression is ubiquitous at the mid-
gestation stage in embryos, followed by more focal expression in various organs in the perinatal 
period and adulthood, notably in the thymus, spleen, lymph nodes, cerebellum, suprachiasmatic 
nuclei, pituitary, olfactory lobes, adrenal medulla, stomach, skin and testes (10). Such an 
expression pattern suggests that Drak2 has a fundamental function in cell biology, and previous 
notion that Drak2 was a T-cell-specific gene is erroneous.  
 
When DAP family kinases are overexpressed in various cells, apoptosis ensues (4-8), indicating 
their involvement in apoptosis. In Drak2 transgenic (Tg) mice, Tg T cells manifest augmented 
apoptosis after TCR stimulation followed by culture in the presence of IL-2; as a consequence, 
the memory T-cell pool is diminished, and these Tg mice incur compromised secondary but not 
primary in vivo T-cell responses (10). The results reveal that Drak2 is important in regulating T-
cell apoptosis both in vitro and in vivo.  
 
In the course of our search for genes affecting islet survival, we discovered that Drak2 
expression in islets was rapidly induced by inflammatory stimuli. The induction was 
accompanied by islet apoptosis. Prevention of such Drak2 upregulation protected β-cells from 
apoptosis; conversely, Drak2 overexpression in Tg islets resulted in increased β-cell death. Mice 
with transplanted Drak2 Tg islets were prone to chronic cytokine stress in vivo. We further 
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identified ribosomal protein S6 p70S6 kinase as a substrate of Drak2. The implications of these 
findings are discussed.  
 
MATERIALS AND METHODS 
Islet purification 
Islets were purified from pancreas of Tg and WT mice, which were in the C57BL/6 background, 
as we described earlier (11, 12). Briefly, 2-ml of digestion solution (Hanks' balanced salt solution 
[HBSS] containing 20 mM HEPES and 2 mg/ml collagenase IV (Worthington Biochemical, 
Lakewood, NJ) were injected into the common bile duct of Tg or wild type (WT) mice (20-24 g) 
after the distal end of the duct was ligated. The distended pancreas was isolated and put into a 
15-ml tube containing an additional 0.5 ml of digestion solution. The pancreas was digested at 
370C for exactly 28 min, and the digestion process was stopped by the addition of 10 ml of cold 
HBSS containing 20 mM HEPES. The islet suspension was filtered through No. 7880 
cheesecloth gauze (Tyco Healthcare, Mansfield, MA) and centrifuged at 500 g for 1-2 min. The 
pellet was washed with cold HBSS once at 500 g for 1-2 min, and the supernatant was removed 
completely. The pellet was then resuspended in 3 ml of 25% Ficoll, and 2-ml layers of 23, 20, 
and 11% Ficoll were added sequentially. The Ficoll gradient was centrifuged at 700g for 5 min. 
Most of the islets were in the interface between the 20 and 23% Ficoll layers and were 
handpicked with Pasteur pipettes. They were then washed twice with cold HBSS. The islets were 
cultured overnight in RPMI 1640 containing 10% FCS, and then used for experimentation. 
 
Treatment of islets with cytokines  
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Isolated islets were cultured in 24-well plates at approximately 200 islets per well in RPMI 1640 
with 10% FCS. IFN-γ (1000 U/ml, TNF-α (200 ng/ml), IL-β (0.5 ng/ml) (R & D Research 
(Burlington, Ontario, Canada), or NG-Methyl-L-arginine acetate salt (L-NMMA; 1 mM) (Sigma, 
Oakville, Ontario, Canada), were added to the wells at the beginning of the culture, as indicated 
in each experiment. 
 
Flow cytometry 
Islets were dispersed into single cells with 0.05% trypsin before flow cytometry. For Drak2 and 
insulin detection, the dispersed islet cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.2% Triton X-100. The cells were stained with rabbit anti-Drak2 Ab 
(Abgent, San Diego, CA) and anti-insulin mAb (Sigma). After wash, the cells were stained with 
FITC-conjugated sheep anti-rabbit antibody (Ab) (Chemicon, Temecula, CA), and PE-
conjugated goat anti-mouse antibody (Jackson Immunoresearch, West Grove, PA), and analyzed 
by 2-color flow cytometry. Dispersed islet cells or small interfering RNA (siRNA)-transfected 
NIT-1 cells were also analyzed for apoptosis by flow cytometry with FITC-annexin V (BD 
Pharmingen, Mississauga, Ontario, Canada) staining (13). Briefly, 5 μl of FITC-annexin V was 
added to each sample of cells in binding buffer (0.01 M HEPES, pH 7.4; 0.14 M NaCl, 2.5 mM 
CaCl2). After 15 min incubation at room temperature, the cells were washed and analyzed by 
flow cytometry. For all flow cytometry, the major population in forward and side scatter 
histograms was gated for further 1- or 2-color analysis, and 5,000 gated events were registered.  
 
Drak2 knockdown by siRNA in NIT-1 cells  
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NIT-1 cells, derived from mouse insulinoma, were transfected with siRNA using Lipofectamine 
2000 (Invitrogen, Burlington, Ontario) according to the manufacturer's instructions. Two siRNAs 
specific for Drak2 were employed. For Drak2 siRNA #1162, the oligonucleotide RNA sequences 
were CAUCCCUGAAGAUGGCAGCtt and GCUGCCAUCUUCAGGGAUGtt. For Drak2 
siRNA #592, the oligonucleotide RNA sequences were UAACAUUGUUCACCUUGAUtt and 
AUCAAGGUGAACAAUGUUAtt. The control siRNA was scrambled  #1162 with the 
following sequences: 5'CCCUAAGUGUAGGACGCACtt and 
3'GUGCGUCCUACACUUAGGGtt. Single-stranded RNA pairs were annealed by incubation 
for 1 min at 900C, and then cooled down to room temperature over 45 min. The final 
concentration of double-stranded siRNA was 10 nM for transfection. In some cases, a mixture of 
#1162 and #592 at 5 nM each was used for transfection. 
  
Confocal microscopy 
Drak2 Tg and WT islets were digested with 0.05% trypsin-EDTA to obtain single cell 
suspensions. The cells were placed on slides by Cytospin (Shandon, Pittsburgh, PA), fixed with 
4% paraformaldehyde and permeabilized with 0.2% Triton X-100. The slides were stained with 
rabbit anti-Drak2 Ab (Abgent, San Diego, CA; 1:50 dilution) and anti-insulin mAb (Sigma, St. 
Louis, MO; 1:500 dilution). Subsequently, the slides were stained with FITC-conjugated sheep 
anti-rabbit antibody (Ab) (Chemicon, Temecula, CA), and PE-conjugated goat anti-mouse 
antibody (Jackson Immunoresearch, West Grove, PA). The cells were visualized under a Carl 
Zeiss confocal microscope, with excitation at 488 nm and emission at 505-550 nm for FITC, and 
with excitation at 543 nm and emission at 560-615 nm for PE. Intracellular Drak2 is shown in 
green, and intracellular insulin is in red.  
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Insulin release assay 
Islets were cultured for 48 h in complete RPMI 1640 medium with 10% FCS in the absence or 
presence of various stimulants; they were then transferred to 12-well plates at a density of 10 
islets/well. The islets were gently washed twice with 1 ml Kreb’s buffer (NaCl, 135 mM; KCl, 
3.6 mM; NaH2PO4, 5 mM; MgCl2, 0.5 mM; CaCl2, 1.5 mM; NaHCO3, 2 mM; HEPES, pH 7.4, 
10 mM; BSA, 0.07%), and then incubated in Kreb’s buffer containing 2.8 mM glucose for 5 min 
at 370C. Two hundred micro litres of supernatant were removed for determination of basal 
insulin levels. The islets were cultured for an additional 40 min, and all the supernatants were 
harvested for the measurement of insulin levels as 2.8 mM glucose-stimulated release. The islets 
were then cultured in Kreb’s buffer containing 16.7 mM glucose for 45 min at 370C, and the 
supernatants were harvested to assess insulin levels as 16.7 mM glucose-stimulated release. 
Insulin was assayed by ELISA (Linco Research, St. Charles, MO). Basal insulin levels, which 
were near zero, were deducted from the 2.8 mM and 16.7 mM glucose-stimulated levels. The 
fold increase in insulin release between 16.7 mM glucose and 2.8 mM glucose stimulation was 
calculated. 
 
Islet transplantation 
Diabetes was induced in C57BL/6 mice by streptozocin (STZ) (200 mg/kg body weight, i.p.). 
After 14 days, syngeneic Tg or WT islets were transplanted into the peritoneal cavity of these 
diabetic mice (400 islets per mouse) to render the recipients euglycemic. Two weeks after islet 
transplantation, glucose tolerance tests were performed to ascertain if the islet reserve capacities 
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of these Tg and WT islet recipients were comparable. The transplanted mice were then injected 
i.v. with multiple low doses of STZ (40 mg/kg/day x 5 days) to assess the incidence of diabetes. 
 
Generation of recombinant proteins 
Full-length cDNAs of Drak2 and p70S6 kinase were cloned into pGEX-4T-1 in-frame 
downstream of the GST coding sequence. These constructs were named pGEX-4T-1-Drak2 and 
pGEX-4T-1-S6K, respectively, and were used to generate GST-tagged Drak2 and p70S6 kinase 
in E. coli. The recombinant proteins were purified with a size exclusion column (Superdex, 2 cm 
in diameter x75 cm in length,) followed by a glutathione-agarose column (GE Healthcare, 
Piscataway, NJ). Drak2 cDNA was also cloned into pCEP4-HA in-frame downstream of a 
coding sequence of 3 HA repeats. The construct was called pCEP4-HA-Drak2 and was 
employed to transfect NIT-1 cells. In some experiments, HA-Drak2 was purified with Sepharose 
conjugated with anti-HA Ab (Covance, Berkeley, CA)   
 
Protein kinase substrate array 
Mouse recombinant Drak2 protein (95% pure according to silver staining) produced from E. coli 
was used as a kinase in the Protoarray Kinase Substrate Identification Kit, which contains 5000 
human protein kinase substrates (Invitrogen, Carlsbad, CA). The reaction was conducted 
according to manufacturer’s instructions. Proteins with a Z-score above 3 (indicating a 
confidence level above 99.9%) are considered potential Drak2 substrates.  
 
Z-score = (the signal value from a given protein minus the mean signal value for all proteins in 
the array)/the signal value of standard deviation for all proteins. 
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In vitro kinase assay 
The autophosphorylation of Drak2 were performed by incubating 0.3 µg HA-Drak2 or GST-
Drak2 protein in kinase buffer (10 mM Tris-HCl [pH 7.5], 10 mM MgCl2, 3 mM MnCl2, 0.5 mM 
CaCl2 and 0.1 mM [γ−32P]-ATP (111 GBq/mmol)(GE Healthcare) in a total volume of 30 µl at 
30°C for 15 min. In some experiments, GST of GST-Drak2 and GST-p70S6 kinase was cleaved 
by thrombin (GE Healthcare) and then used in the in vitro kinase assay. The kinase reactions 
were terminated by adding 10 µl of 3x SDS-polyacrylamide gel electrophoresis (PAGE) loading 
buffer. The proteins were resolved by SDS-PAGE, transferred to nitrocellulose membrane, and 
autoradiographed.  
 
Immunoblotting 
NIT-1 cells were transiently transfected with pCEP4-HA-Drak2 or empty vector pCEP4-HA. 
After 48 h, the cells were lysed and resolved in 10% SDS-PAGE (60 μg/lane) followed by 
immunoblotting. For HA-Drak2 expression, membrane was blotted with mouse anti-HA mAb 
(Santa Cruz, Santa Cruz, CA; 1:1000 dilution) followed by horse radish peroxidase (HRP)-
conjugated sheep anti-mouse IgG (GE Healthcare; 1:2000 dilution). To assess p70S6 kinase 
phosphorylation, the membrane was blotted with mouse anti-phospho-p70S6 kinase (Thr389) Ab 
(Cell Signaling, Danvers, MA; 1:1000 dilution) followed by HRP-conjugated sheep anti-mouse 
IgG (GE Health; 1:2000 dilution). The membrane was also blotted with rabbit anti-p70S6 kinase 
Ab (Cell Signaling, Danvers, MA; 1:1000 dilution) followed by HRP-conjugated donkey anti-
rabbit IgG to show similar total p70S6 kinase protein. In some experiments, NIT-1 cells were 
stimulated with IFN-γ (1000U/ml) plus IL-1β (0.5 ng/ml), or TNF-α (200ng/ml) plus IL-1β (0.5 
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ng/ml). Twenty four hours later, they were transfected with two different Drak2 siRNAs (#592 
and #1162), or with a control siRNA. After additional 24 h, phospho-p70S6 kinase and total 
p70S6 kinase in the cell lysates were detected in immunoblotting.  For caspase-9 detection, NIT-
1 cells were stimulated with cytokines and transfected with a mixture of 2 Drak2 siRNAs (#592 
and #1162; 5 nM each) or with a control siRNA to #1162 (10 nM) at the beginning of culture. 
Twenty-four hours later, the cells were lysed and resolved in 10% SDS-PAGE (60 μg protein 
/lane). The membranes were blotted with anti-caspase-9 Ab (Cell Signaling; 1:1000 dilution) 
followed by HRP-conjugated donkey anti-rabbit IgG (GE Health; 1:2000 dilution). After that the 
membrane was stripped and blotted with anti-β-actin Ab (Cell Signaling; 1:1000 dilution) as a 
loading control. 
 
RESULTS 
Rapid induction of Drak2 expression in islet β-cells 
We treated islets with a combination of IFN-γ and IL-1β or TNF-α and IL-1β, which are 
reported to cause islet apoptosis in type 1 diabetes (14,15). The islets were harvested 2 h, 6 h and 
24 h after the cytokine stimulation. We found that these cytokines induced Drak2 mRNA 
expression in isolated islets within 24 h (Figs. 1A and 1B). We next assessed Drak2 protein 
levels in β-cells stimulated with IFN-γ plus IL-1β, or TNF-α plus IL-1β, employing anti-insulin 
mAb and anti-Drak2 Ab in 2-color flow cytometry. Histograms of a representative kinetics study 
at 0 h, 6 h, 24 h and 48 h was shown in Fig. 2. In islets culture in medium, Drak2 protein levels 
in insulin-positive β-cells were nearly constant for 24 h (44.7-47.2%), but then it increased to 
63.8% at 48 h (first row). The presence of inflammatory cytokines, i.e., IFN-γ plus IL-1β, or 
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TNF-α plus IL-1β, induced rapid upregulation of Drak2 as early as 6 h; the elevated cytokine-
stimulated expression last until 48 h, compared to that of cells in plain medium. 
 
Drak2 knockdown by siRNA protected NIT-1 insulinoma cells from cytokine-triggered 
apoptosis  
To prove that Drak2 was indeed critical to cytokine-induced β-cell apoptosis, we employed 
siRNA to prevent Drak2 upregulation in NIT-1 insulinoma cells. As shown in Fig. 3A, similarly 
to normal β-cells, Drak2 protein was induced in NIT-1 cells by IFN-γ plus IL-1β (3rd column, 
top panel) or TNF-α plus IL-1β (3rd column, lower panel). siRNA prevented Drak2 protein 
upregulation stimulated by IFN-γ plus IL-1β and TNF-α plus IL-1β (1st column, Fig. 3A). 
Control siRNA had no effect on Drak2 levels (2nd column, Fig. 3A). A bar graph summarizing 4-
5 independent experiments is shown in Fig. 3B. As in normal islet cells, these stimuli induced 
NIT-1 cell apoptosis after 24 h (3rd column, Fig. 3C). However, with protection by Drak2 siRNA 
(1st column) but not control siRNA (2nd column), such apoptosis induction by IFN-γ plus IL-
1β (top panel) or TNF-α plus IL-1β (lower panel) was dampened. A bar graph summarizing data 
from 4-5 independent experiments is shown in Fig. 3D. These results confirmed the detrimental 
role of Drak2 in islet β-cell survival. 
 
The position of Drak2 in the INF-γ/IL-1β -triggered β-cell apoptosis pathway 
It is known that INF-γ/IL-1β-mediated β-cell apoptosis is mediated by nitric oxide (NO) (2). To 
locate the position of Drak2 in relation to NO in this model, we assessed Drak2 induction in the 
presence of L-NMMA, an inhibitor of inducible nitric oxide synthase (iNOS).  As shown in Fig. 
3E, L-NMMA potently inhibited INF-γ plus IL-1β−induced Drak2 augmentation, and this clearly 
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placed Drak2 downstream of NO in this apoptosis pathway. We further detected procaspase-9 
cleavage in NIT-1 cells after IFN-γ plus IL-1β or TNF-α plus IL-1β stimulation, and such 
cleavage was reduced (Fig. 3F), accompanied by reduced NIT-1 cell apoptosis (Figs. 3C and 3D) 
when Drak2 expression was knocked down by Drak2 siRNA. This indicated that caspase-9 was 
downstream of the cytokine/NO/Drak2 pathway in β-cell apoptosis.  
 
Transgenic Drak2 overexpression in Tg islets aggravated cytokine-triggered apoptosis  
The role of Drak2 in islet survival was further validated using actin promoter-driven Drak2 Tg 
mice which we generated recently (10). These mice are viable, fertile, and have no gross 
anomalies (10). The WT and Drak2 Tg pancreases had similar islets number and size, according 
to histological examination and number of islets isolated (data not shown). We demonstrated 
(Fig. 4A) that Drak2 mRNA was about 4 times higher in Tg islets than in WT islets. 
Immunofluorescence study revealed elevated Drak2 protein levels in insulin-positive Tg β-cells 
(Fig. 4B), although their forward and side scatter (representing size and granularity of islet cells) 
in flow cytometry were similar (left column, Fig. 5A). The inflammatory cytokines (IFN-γ plus 
IL-1β or TNF-α plus IL-1β) induced WT islet cell apoptosis after 48 h (Figs. 5A and 5B, top 
rows), as expected. However, Tg islet cells underwent increased apoptosis compared with WT 
islet cells when stimulated with IFN-γ plus IL-1β or TNF-α plus IL-1β (bottom rows, Figs. 5A 
and 5B). A summary of data from 4-6 experiments are given in Fig. 5C. Insulin release assay 
demonstrated that the β-cell function of Tg islets assaulted by cytokines was significantly lower 
than that of WT islets (Fig. 5D). Since Tg islets treated with cytokines had significantly 
increased apoptosis compared with WT islets, the compromised β-cells function seen in insulin 
release assay pinpointing the apoptotic islet cells  to β-cells, although we cannot exclude the 
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possibility that the cytokines also damaged the function of live β-cells. These in vitro 
experiments confirmed that augmented Drak2 expression was harmful to β-cell survival.  
 
Drak2 overexpression led to increased diabetes incidence in vivo 
The proapoptotic effect of Drak2 in β-cells in vitro raised a logical question as to whether its 
overexpression would render mice prone to diabetes. In our Tg mice, Drak2 expression was not 
restricted to islets as it was driven by the actin promoter (10). To pin-point the in vivo phenotype 
to islets, we transplanted Tg or WT islets to full-dose STZ (200 mg/kg)-induced diabetic mice, 
which were syngeneic to the donors. Once the recipients became normoglycemic, glucose 
tolerance tests were performed to ascertain that they had similar reserve islet capacity (data not 
shown). These recipients were then injected with multiple low-doses of STZ to induce borderline 
diabetes in WT islet recipients. Islet damage by such a STZ regimen is reported to cause chronic 
inflammatory environment in the pancreas (16, 17). After STZ injection, the blood glucose levels 
of WT mice hovered around 12 mM (Fig. 5E). However, such treatment caused full-blown 
diabetes in Tg islet recipients from days 15 to 18 post STZ treatment (Fig. 5E), with their blood 
glucose rising above 20 mM. This finding clearly indicates that Drak2 overexpressed in Tg islets 
is responsible for the diabetes-prone phenotype in the recipients. 
 
Identification of p70S6 kinase as a Drak2 substrate in vitro 
To understand the mechanism of Drak2 action, we attempted to discover the substrate of Drak2. 
Recombinant mouse GST-Drak2 was generated with the construct pGEX-4T-1-Drak2, and was 
prepared to more than 95% purity after size fractionation followed by affinity purification (Fig. 
6A, 1st and 2nd lanes). Its kinase activity was confirmed by autophosphorylation in an in vitro 
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kinase assay (Fig. 6B). It was then employed as the kinase in an assay with the Invitrogen 
Protoarray Kinase Substrate Identification Kit, which contained 5,000 potential kinase substrate 
proteins of human origin. Five proteins showed a Z-score above 3, a threshold indicating more 
than 99.9% confidence. Among the 5 proteins, one was p70S6 kinase.  
 
To confirm that mouse Drak2 could phosphorylate mouse p70S6 kinase, GST-tagged mouse 
p70S6 kinase was generated with the construct pGEX-4T-1-p70S6K, and processed to more that 
95% purity after affinity purification followed by cleavage of GST by thrombin (Fig. 6C). Mouse 
Drak2, which was also more than 95% pure (Fig. 6A, 3rd lane) after affinity purification followed 
by cleavage of GST by thrombin, served as a kinase in an in vitro kinase assay, using mouse 
p70S6 kinase as a substrate. As illustrated in Fig. 6D, Drak2 could autophosphorylate itself, as 
expected (lane 1). It also phosphorylated mouse p70S6 kinase (lane 1). On the other hand, p70S6 
kinase could not autophosphorylate (lane 2) in the kinase assay. Thus, the phosphorylation on 
mouse p70S6 kinase was caused by Drak2, and p70S6 kinase was a bona fide Drak2 substrate in 
vitro. 
 
Identification of p70S6 kinase as a Drak2 substrate in vivo 
Next, we attempted to demonstrate that p70S6 kinase was a Drak2 substrate inside the cells (in 
vivo). NIT-1 cells were transiently transfected with a HA-tagged Drak2 expression construct 
pCEP4-HA-Drak2. HA-tagged Drak2 was affinity-purified, and it showed the expected size in 
immunoblotting (Fig. 7A). It was tested in an in vitro kinase assay and could autophosphorylate 
itself, as illustrated in Fig. 7B, proving that the recombinant protein possessed active kinase 
activity. When NIT-1 cells were transiently transfected with pCEP4-HA-Drak2 or an empty 
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vector, recombinant HA-Drak2 expression at the size of 45 kD could be detected by anti-HA Ab 
in immunoblotting in the former but not in the latter transfected cells, as seen in Fig. 7C (lane 1 
versus lane 2, top panel). In pCEP4-HA-Drak2-transfected cells (lane 1, middle panel, Fig. 7C) 
but not empty vector-transfected cells (lane 2, middle panel, Fig. 7C), p70S6 kinase 
phosphorylation was augmented, while total p70S6 kinase protein remained constant (bottom 
panel, Fig. 7C). This indicates that Drak2 overexpression in vivo led to increased p70S6 kinase 
phosphorylation, and corroborates our in vitro kinase assay that p70S6 kinase was a Drak2 
substrate. 
 
Further in vivo verification of the relationship between Drak2 and p70S6 kinase phosphorylation 
was undertaken by knocking down Drak2 expression with siRNA. As depicted in Fig. 8, IFN-γ 
plus IL-1β or TNF-α plus IL-1β induced Drak2 protein expression (the 2nd and 3rd columns, 
compared with the 1st column; Fig. 8A). This was accompanied by increased p70S6 kinase 
phosphorylation (the 2nd and 3rd lanes, compared with the 1st lane, Fig. 8B; the 2nd and 3rd 
columns, compared with the 1st column, Fig. 8C). Control siRNA had no effect on Drak2 
induction (the last 2 columns compared with the 2nd and 3rd columns, Fig. 8A), nor did it on 
p70S6 kinase phosphorylation (the last 2 lanes compared with the 2nd and 3rd lanes, Fig. 8B; last 
the 2 columns compared with the 2nd and 3rd columns, Fig. 8C). However, 2 different Drak2 
siRNAs knocked down cytokine-induced Drak2 expression (columns 5, 6, 8, and 9, compared 
with columns 2 and 3, Fig. 8A), and this was accompanied by reduced cytokine-induced p70S6 
kinase phosphorylation (lanes 5, 6, 8 and 9, compared with lanes 2 and 3, Fig. 8B; columns 5, 6, 
8, and 9, compared with columns 2 and 3, Fig. 8C). This further confirms that p70S6 kinase was 
a Drak2 substrate in vivo. 
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To study the relevance of p70S6 kinase in β-cell apoptosis, we used rapamycin to inhibit 
mTORC1, which is another kinase capable of phosphorylating p70S6 kinase. NIT-1 cells under 
rapamycin protection showed reduced apoptosis upon IFN-γ plus IL-1β or TNF-α plus IL-
1β exposure (Fig. 8D), and a bar graph summarizing data from 2 independent experiments is 
shown in Fig. 8E. Taking our Drak2 and rapamycin results together, we believe that p70S6 
kinase activity is required for β-cell apoptosis. 
 
DISCUSSION 
 
In this study, we demonstrated that Drak2 is critical for β-cell apoptosis triggered by 
inflammatory cytokines. Further in vivo experiments proved that enhanced Drak2 expression in 
islets rendered mice prone to diabetes in a model of STZ-induced islet stress.  We further 
discovered that p70S6 kinase was a substrate of Drak2. 
 
Drak2 Tg islets manifested increased apoptosis after cytokine assaults (Figs. 5A and 5B). 
However, without such assaults, apoptosis of Tg islets cultured in medium was not different from 
that of WT islets. This suggests that Drak2 overexpression, by itself, is not sufficient to cause β-
cell apoptosis, but rather the overexpression renders β-cells vulnerable to signalling from other 
detrimental factors. Indeed, islet β-cell apoptosis often needs concerted signals from different 
pathways. For example, single cytokine such as TNFα, IFNγ or IL-1β does not have a significant 
effect on β-cells, but a combination of 2 or 3 of them potently induces their apoptosis (2). It is to 
be noted that while it took 24 h to reach peak Drak2 induction by a combination of two cytokines 
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such as IFN-γ plus IL-1β or TNF-α plus IL-1β, Drak2 expression peaked faster at 5 h after the 
stimulation of IFN-γ, TNF-α and IL-1β in combination, accompanied by a higher degree of 
apoptosis (data not shown). This indicates that 1) multiple detrimental factors are additive to islet 
apoptosis, and 2) Drak2 is a common mediator in multiple cytokine signalling pathways. The 
latter notion is further supported by a finding that another detrimental factor, FasL, could also 
induce Drak2 expression in islets (data not shown), and that Drak2 Tg islets treated with FasL in 
combination with IFN-γ presented increased apoptosis compared with WT islets. Our finding is 
also consistent with the fact that type 1 diabetes is under polygenic control, and abnormal 
expression of a single gene rarely induces diabetes.  
 
In humans, the Drak2 gene is located in 2q33.2, and is 7.2 Mbp from a type 1 diabetes risk locus 
IDDM12 at 2q33.2. Although CTLA-4 has been identified in this locus (18), whether there are 
additional type 1 diabetes risk genes in this area needs to be assessed. Single nucleotide 
polymorphism analysis of Drak2 gene and genes that regulate Drak2 expression in type 1 
diabetes versus normal individuals will answer the question whether Drak2 is a bona fide type 1 
diabetes risk gene in humans.  
 
Obviously, if Drak2 is a diabetes risk factor, genes in the Drak2 pathway could all be involved in 
such a risk, and genetic studies aimed at validating Drak2 as a diabetes risk factor should include 
genes in its signalling pathway.  
 
Our prior knowledge about the Drak2 activation pathway and Drak2 substrates is limited. In this 
study, we found that an iNOS inhibitor L-NMMA could effective block IFN-γ/IL-1β induced 
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Drak2 expression, and thus placed NO upstream of Drak2 in this particular cytokine pathway. 
We also demonstrated Drak2 acted through caspase-9 in apoptosis, although our study on 
caspase-8 activation was not conclusive (data not shown). Concerning the direct Drak2 
substrate(s), we only knew before that Drak2 is a genuine substrate of itself. In this study, we 
identified 5 putative Drak2 substrates, and proved that p70S6 kinase was a bona fide Drak2 
substrate in vitro and in vivo. Verification of the other 4 substrates is ongoing, and it is quite 
possible that Drak2 has multiple substrates.  
 
p70S6 kinase plays a critical role in protein synthesis, and is a key regulator in cell size and cell 
cycle progression. It is activated through phosphorylation, which is triggered by a wide range of 
growth factors, cytokines and nutrients (19). mTORC1 and PDK1 are 2 known kinases which 
work in concert to phosphorylate and activate p70S6 kinase. We have identified a novel p70S6 
kinase signalling pathway in which Drak2 was an additional upstream kinase capable of 
phosphorylating p70S6 kinase. According to our data, the inflammatory cytokine/Drak2/p70S6 
kinase pathway seems to be critical in islet apoptosis, because the action of all these 3 
components was correlated to islet apoptosis, and they were sequentially linked. Inhibitors of 
components of this pathway should have protective effects on β-cells.  
 
Interestingly, islet transplantation efficiency has been greatly improved after rapamycin, a 
mTORC1 inhibitor, replaced the calcineurin inhibitor cyclosporin A in the islet transplantation 
regimen (20). It is possible that p70S6 kinase is critical in islet apoptosis and that inhibition of 
p70S6 kinase phosphorylation by rapamycin contributes to the reduction of islet apoptosis after 
transplantation; hence, this is partially responsible for the increase in transplantation efficiency. 
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We have further in vitro evidence that rapamycin rendered β-cells partially resistant to apoptosis 
induced by cytokines, suggesting that p70S6 kinase is relevant to islet survival. It is possible that 
inflammatory cytokines activate both the Drak2/p70S6 kinase and mTORC1/p70S6 kinase 
pathways, and that inhibiting one of them is only partially effective in reducing β-cell apoptosis. 
Indeed, when Drak2 upregulation stimulated by cytokines was prevented by siRNA, islet 
apoptosis was decreased, but was not totally prevented. Similarly, rapamycin only partially 
protected islet apoptosis from the cytokines. Dual inhibition of mTORC1 (with rapamycin) and 
Drak2 (with Drak2 inhibitors that are to be developed) might achieve better results in islet 
protection in terms of cytokine-induced β-cell apoptosis.  
 
With that said, we read with interest a recent report by Freankel et al., in which the authors 
demonstrated that mTOR inhibition by rapamycin exacerbates type 2 diabetes, and reduced islet 
mass in diabetes P. obesus (21). This result seems to be in conflict with our findings that 
rapamycin protected β-cells from apoptosis, and previous reports showing that p70S6 kinase 
gene knockout leads to increased insulin sensitivity (22) and that overactivation of mTOR/p70S6 
kinase is responsible for impaired insulin action (23). A possible explanation is that rapamycin’s 
effect on other targets such as mTORC2, and/or 4EBP1 via mTORC1 might be detrimental to β-
cell viability in a type 2 diabetes environment. If this is the case, Drak2 inhibitors which target 
p70S kinase activation alone without affecting mTORC2 and 4EBP1 might have advantage over 
rapamycin in protecting islets from apoptosis.  
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FIGURE LEGEMDS 
Figure 1. Drak2 mRNA was rapidly augmented in islets encountering 
inflammatory stimulation 
 
Drak2 mRNA expression in C57BL/6 islet cells was measured by real time RT-PCR. 
The ratio of Drak2 mRNA and β-actin mRNA was taken as a measure of Drak2 mRNA 
levels. The samples were in triplicate, and the means + SD of 5 to 6 independent 
experiments are shown.  
A. Islets were stimulated by IFN-γ (1,000 U/ml) plus IL-1β (0.5 ng/ml) in vitro for 24 h. 
B. Islets were stimulated by TNF-α (200 ng/ml) plus IL-1β (0.5 ng/ml) in vitro for 24 h. 
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Figure 2. Flow cytometry analysis of Drak2 protein upregulation in β-cells 
upon inflammatory stimuli  
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C57BL/6 islets were cultured for 0, 6 24 and 48 h in the absence or presence of IFN-γ 
plus IL-1β, or TNF-α plus IL-1β, as described in Fig. 1. The islets were dispersed after 
culture and analyzed by 2-color flow cytometry for intracellular insulin and Drak2. The 
experiment was repeated twice. Histograms from a representative experiment are 
shown. The first column showed the isotypic control for Drak2 and insulin staining 
(upper panel), and Drak2 expression at 0 h (lower panel). Insulin positive cells were 
gated and their Drak2 expression was presented in one-color histograms. The staining 
background according to isotypic control has been deducted from all percentages 
shown.  
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Figure 3. Drak 2 signalling is responsible for β-cell apoptosis  
 
A and B. Drak2 siRNA inhibited Drak2 protein upregulation in NIT-1 insulinoma 
cells 
NIT-1 insulinoma cells were cultured in the absence or presence of IFN-γ plus IL-1β, 
or TNF-α plus IL-1β, as described in Fig. 1. Twenty-four hours after the initiation of 
incubation, the cells were transfected with Drak2 siRNA (#1162) or control siRNA 
(scrambled #1162). The cells were harvested at 48 h and analyzed for intracellular 
Drak2 protein levels by flow cytometry. The experiment was repeated 4 to 5 times. 
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Histograms of a representative experiment are shown in (A). Shaded areas are isotypic 
controls. The staining background (isotypic control) has been deducted from all 
percentages shown.  Means + SD of these 4-5 experiments are shown in (B) (n=4 or 
n=5, as indicated). Asterisks indicate p values (<0.05) of siRNA- versus control 
siRNA-treated cells, according to Student’s t test. 
 
C and D. Drak2 siRNA prevented cytokine-induced apoptosis in NIT-1 cells 
NIT-1 cells were cultured in the absence or presence of IFN-γ plus IL-1β, or TNF-α 
plus IL-1β, as described in Fig. 1. Twenty-four hours after the initiation of incubation, 
the cells were transfected with Drak2 siRNA (#1162) or control siRNA. The cells were 
harvested at 48 h and analyzed for apoptosis by flow cytometry with annexin V staining. 
The experiment was repeated 4 to 5 times. Histograms of a representative experiment 
are shown in (C). Means + SD of percentage of apoptosis in all these independent 
experiments (n=4 or n=5, as indicated) are shown in (D). Asterisks indicate p values 
(<0.05) of siRNA- versus control siRNA-treated cells, according to Student’s t test. 
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E. iNOS inhibitor L-NMMA blocks Drak2 cytokine-induced Drak2 upregulation 
Islets were cultured in the absence or presence of IFN-γ plus IL-1β and 1 mM L-
NMMA. After 24 h, the islets were harvested and their Drak2 mRNA was measured by 
real-time RT-PCR. The ratio of Drak2 mRNA and β-actin mRNA was taken as a 
measure of Drak2 mRNA levels. The samples were in duplicate, and the means + SD of 
3 independent experiments are shown.  
 
F. Drak2-induced apoptosis utilized the caspase-9 pathway 
NIT-1 insulinoma cells were simply cultured or transfected with Drak2 siRNA (a 
mixture of #592 and #1162 at 5 nM each) or control siRNA (10 nM), and stimulated by 
IFN-γ plus IL-1β, or TNF-α plus IL-1β, as indicated. After 24 h, the cells were 
 FACULTÉ  DES  ÉTUDES  SUPÉRIEURES  UNIVERSITÉ  DE  MONTRÉAL           JIANNING MAO                             160
harvested, and pro-caspase-9 cleavage was detected by Western blotting (upper panel). 
The positions of pro-caspase-9 and cleaved caspase-9 (c-caspase-9) are indicated. The 
same membrane was blotted with anti-β-actin (lower panel) to show even protein 
loading.  
 
Figure 4. Drak2 overexpression in Tg islet β-cells 
 
A. Drak2 mRNA overexpression in Tg islets 
Islets from actin promoter-driven Drak2 Tg mice or their WT littermates were isolated 
and Drak2 mRNA levels were measured by real time RT-PCR. The samples were in 
duplicate. Means + SD of Drak2/β-actin mRNA ratios of 2 independent experiments 
are shown. 
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B. Drak2 protein overexpression in Tg β-cells 
Drak2 Tg or WT islets were analyzed by confocal microscopy for Drak2 and insulin 
expression. The Drak2 signal is in green, and insulin, in red. Representative data from 2 
experiments are shown. 
 
Figure 5. Drak2 Tg islets were prone to apoptosis upon inflammatory cytokine 
stimulation 
 
A-C. Flow cytometry analysis of islet cell apoptosis 
Drak2 Tg and WT islets were cultured in RPMI 1640 medium with 10% FCS and 
stimulated with IFN-γ (1000 U/ml) plus IL-1β (0.5 ng/ml) or TNF-α (200 ng/ml) plus 
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IL-1β (0.5 ng/ml). After 24 and 48 h, the islets were dispersed and analyzed by flow 
cytometry with annexin V staining. The percentage of annexin V-positive cells is 
shown in the histograms. The experiment was repeated more than 4-6 times. A 
representative set of data is shown in Figs. 4A and 4B, and a data summary from 48-h 
cultures appears in Fig. 4C, with the number of experiments (n) indicated. Asterisks 
indicate p<0.05 according to paired Student’s t test. 
 
D. Insulin release assay of islets after cytokine stimulation  
Islets from Tg or WT mice were cultured in the presence or absence of IFN-γ (1000 
U/ml) plus IL-1β (0.5 ng/ml), or TNF -α (200 ng/ml) plus IL-1β (0.5 ng/ml). Insulin 
release by these islets (10 islets/treatment/well) was measured after 48 h. Samples were 
in duplicate. Means + SD of the results of 4 determinants from 2 independent 
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experiments are shown in terms of fold increase in insulin release stimulated by 16.7 
mM versus 2.8 mM glucose. 
 
E.  Increased STZ-induced diabetes incidence in mice with transplanted Drak2 Tg 
islets 
Diabetes was induced in C57BL/6 mice by a single i.p. STZ injection (200 mg/kg body 
weight). After 14 days, the diabetes status of these mice was confirmed according to 
blood glucose levels. WT or Tg islets were then transplanted i.p. to these diabetic mice 
to achieve euglycemia. After another 14 days, the glucose tolerance of these mice was 
verified to be similar (data now shown). Multiple low doses of STZ (40 mg/kg body 
weight/day x 5 days) were subsequently given i.v. to these islet transplant recipients. 
Their blood glucose levels from day 0 (the day after multiple low doses of STZ 
injection was terminated) to day 18 are shown. From days 15 on, the blood glucose 
levels of the Tg and WT islet recipients are significantly different (p<0.05, Student’s t 
test). 
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Figure 6.  p70S6 kinase phosphorylation by Drak 2 in vitro 
 
A. Generation of recombinant GST-Drak2 
GST-Drak2 was produced in E. coli with the construct pGEX-4T-1-Drak2. The 
recombinant protein was first affinity-purified with glutathione-agarose beads, followed 
by size-exclusion chromatography. The purified protein appeared at the expected size 
(71 kD) and was more that 95% pure according to Coomassie Blue (1st lane) and silver 
staining (2ndlane). In some experiments, the GST tag of GST-Drak2 was cleaved by 
thrombin during affinity purification, and the purity of the untagged Drak2 was more 
than 95%, according to Coomassie Blue staining (3rd lane). 
 
B. GST-Drak2 was kinase-active 
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GST-Drak2 was employed in an in vitro kinase assay. The product of the assay was 
resolved by 12% SDS-PAGE, followed by autoradiography. A distinct radio-labeled 
band at the expected size of GST-Drak2 (71 kD) was detected.  
 
C. Generation of recombinant GST-p70S6 kinase  
GST-p70S6 kinase was produced in E. coli with the construct pGEX-4T-1-p70S6K. 
The recombinant protein was first affinity purified with glutathione-agarose beads, 
followed cleavage of the GST-tag by thrombin. The purified protein appeared at the 
expected size (53 kD) with more than 95% purity, according to Coomassie Blue 
staining. 
  
D. p70S6 kinase phosphorylated by Drak2 in vitro 
Mouse recombinant Drak2 and p70S6 kinase were reacted in an in vitro kinase assay. 
The product of the reaction was resolved by 12% SDS-PAGE, followed by 
autoradiography. Distinct radio-labeled bands at the expected sizes of Drak2 (45 kD) 
and S6 kinase (53 kD) were detected (lane 1). In lane 2, p70S6 kinase alone was 
present in the in vitro kinase assay without Drak2, and no radioactive band was 
detected. 
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Figure 7. Drak 2 phosphorylated  p70S6 kinase in vivo 
 
A. Expression of HA-Drak2 in NIT-1 cells 
NIT-1 cells were transiently transfected with pCEP4-HA-Drak2. After 48 h, 
recombinant HA-Drak2 was affinity-purified from the cell lysates with anti-HA agarose, 
followed by HA peptide elution. The purified protein was resolved in 12% SDS-PAGE, 
and immunoblotted with anti-HA Ab. Left lane: protein purified from pCEP4-HA-
Drak2-transfected NIT-1 cells; right lane: protein purified from empty vector pCEP4-
HA transfected NIT-1 cells using the same procedure. 
 
B. Recombinant HA-Drak2 was kinase-active 
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HA-Drak2, affinity-purified from in pCEP4-HA-Drak2-transfected NIT-1 cells, was 
employed in an in vitro kinase assay. The product of the assay was resolved by 12% 
SDS-PAGE, followed by autoradiography. A distinct radio-labeled band at the 
expected size of HA-Drak2 (45 kD) was detected (left lane). No radio-labeled band was 
detected using a sample purified from empty vector-transfected NIT-1 cells (right lane). 
 
C. Drak2 overexpression led to enhanced p70S6 kinase phosphorylation in vivo 
NIT-1 cells were transiently transfected with pCEP4-HA-Drak2 (left lane) or empty 
vector pCEP4-HA (right lane). After 48 h, the cells were harvested, and the lysates 
were analyzed with immunoblotting. Upper panel: the membrane was blotted with anti-
HA to ascertain the HA-Drak2 overexpression; middle panel: the membrane was 
blotted with anti-phospho-p70S6 kinase to assess p70S6 kinase phosphorylation; 
bottom panel: the membrane was blotted with anti-p70S6 kinase to ascertain the similar 
total p70S6 kinase levels in NIT-1 cells transfected with pCEP4-HA-Drak2 or the 
empty vector pCEP4-HA. 
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Figure 8. Effect of Drak2 siRNA on p70S6 kinase phosphorylation and of rapamycin on 
β-cell apoptosis 
 
A-C. Drak2 siRNA inhibited p70S6 kinase phosphorylation in vivo 
NIT-1 cells were stimulated with IFN-γ (1000 U/ml) plus IL-1β (0.5 ng/ml), or TNF -
α (200 ng/ml) plus IL-1β (0.5 ng/ml). After 24 h, they were transfected with 2 different 
Drak2 siRNAs (#592 and #1162), or with a control siRNA, which had a scrambled 
sequence of siRNA #1162. Drak2 protein expression at 48 h was assayed by flow 
cytometry (Fig. 8A). Phospho-p70S6 kinase (upper panel) and total p70S6 kinase 
(lower panel) in the cell lysates were detected by immunoblotting (Fig. 8B). The ratio 
of phospho-p70S6 kinase and total p70S6 kinase signals according to densitometry 
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were expressed in a bar graph (Fig. 8C). The experiment was conducted twice, and a 
representative one is shown. 
 
D and E. Rapamycin protected NIT-1 cells from  cytokine-induced apoptosis 
NIT-1 cells were stimulated with IFN-γ (1000 U/ml) plus IL-1β (0.5 ng/ml), or TNF -
α (200 ng/ml) plus IL-1β (0.5 ng/ml) for 48 h in the presence or absence of rapamycin 
(250 nM). Their apoptosis was assessed by annexin V staining followed by flow 
cytometry. The experiment was conducted twice. Histograms of a representative 
experiment are shown in (D), and the means + SD of 2 indepent experiments are shown 
in (E). The asterisks indicate highly significant difference (p<0.05, Student’s t test). 
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   III. DISCUSSION 
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III.    Discussion 
As a part of my Ph.D. program, I and my collaborators mapped the expression pattern 
of Drak2 during ontogeny, found that Drak2 was critical in T-cell apoptosis and 
memory T-cell development, discovered that Drak2 was a T1D and T2D risk factor, 
and revealed that p70S6 kinase was a substrate of Drak2. The results of our study are 
discussed below. 
1. Expression of Drak2 
In our study, firstly we checked the Drak2 expression level. Although previous report 
claims that Drak2 expression is T cell-specific (1), employing ISH, we found that 
Drak2 was ubiquitously expressed during the mid-gestation stage. Later, in adult mice, 
Drak2 expression became more restricted with high levels in the thymus, spleen, and 
lymph nodes; however, many other regions and organs, such as the olfactory lobe, 
ventricular zone, hippocampal area CA1, intermediate lobe, anterior lobe, 
suprachasmiatic nuclei in the brain, the glandular and nonglandular regions in the 
stomach, the adrenal medulla, skin, and testes also showed prominent Drak2 
expression. The signal of Drak2 in the adult brain probably suggests that it play an 
important role other than apoptosis. The ubiquitous expression of Drak2 in the mid-
gestation stage also indicates that Drak2 participates in embryonic development. The 
broad expression pattern of Drak2 indicates that it is an important kinase whose 
function is not restricted in lymphoid organs. Till now, the studies on Drak2 have been 
mainly focused on the immune system (1-4),  and we are the first ones who have 
discovered the role of Drak2 in islet beta cell function and survival.  
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2. The physiological role of Drak2 in T cell homeostasis  
Previously, study on Drak2 knockout mouse claims that Drak2 is not involved in T cell 
apoptosis (1). They found Drak2–/– mice have enhanced T cell activation and are 
resistant to experimental autoimmune encephalomyelitis, an autoimmune demyelinating 
disease that resembles multiple sclerosis (1). Recent study by the same group on 
knockout mouse show that  Drak2–/– T cells require greater tonic signaling for 
maintenance during clonal expansion. Following stimulation, Drak2–/– T cells were 
more sensitive to an intrinsic form of apoptosis that was prevented by CD28 ligation, 
homeostatic cytokines, or enforced Bcl-xL expression. T cell-specific Bcl-xL expression 
also restored the susceptibility of Drak2–/– mice to experimental autoimmune 
encephalomyelitis (3). 
How do we reconcile the two opposite findings, one with KO null mutation showing 
that Drak2 is not important or even anti-apoptotic, and one with Tg overexpression 
showing that it is proapoptotic? We are almost sure that McGargill et. al. did not 
conduct a careful investigation and hastly made their conclusion that Drak2 has no role 
in T-cell apoptosis (1). Their second study demonstrating that drak2-/- T cells are more 
sensitive to an intrinsic form of apoptosis seems to be better conducted. It’s known that 
after an infection is cleared, there are two forms of apoptosis in clonal contraction:  
activation-induced cell death (AICD) and activated cell autonomous death (ACAD) (5). 
AICD is thought to depend on an extrinsic form of apoptosis induced by the ligation of 
death receptors such as Fas on the surface of the T cell  (6). Which program is activated 
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is largely depended on the antigen. AICD is the prevailing mechanism if antigens are 
present at higher concentrations at the early stage of immune response.  ACAD, in 
contrast, might be the dominating mechanism at the end of the immune response when 
foreign antigen is present only at very low concentrations (5).  
We found that Drak2 mRNA level in activated T cell showed a peak at 90 minute, 
followed by a decrease after 24 hour. Although the meaning of the rapid surge is not 
clear, this probably suggests that Drak2’s level needs to be precisely regulated during 
an immune response. It’s possible at the early stage of T-cell activation, the up-
regulation of Drak2, which happens within hours, instructs the apoptosis of activated T 
cells by AICD; the overexpression of Drak2 in Tg mouse at this stage leads to increased 
cell death. On the other hand, after 24 hour, Drak2 is down-regulated and kept at a low 
level. The low level of Drak2 probably prevents excessive apoptosis of AICD by raising 
their threshold of vulnerability toward IL-2. Also, a certain low level of Drak2 is 
needed at this stage to prevent excessive apoptosis caused by ACAD. The complete 
deletion of Drak2 in knockout mouse leads to increased ACAD in T cells, which can be 
rescued by CD28 ligation or enforced Bcl-XL expression.  
 
3. Drak2 might work on a two-hit model 
The expression of Drak2 increases when WT T cells are activated or when WT islet β 
cells are under treatment. However, Drak2 transgenic T cells didn’t show the tendency 
of apoptosis until exogenous IL-2 was added. Also, the difference between transgenic 
and WT islets apoptosis can only be found under cytokine or free fatty acid treatment.  
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This suggests that Drak2 might act on a two-hit mode, in which other signalling events 
(hit 1) derived from stimulation as well as Drak2 (hit 2) are both required to results in 
cell damage and/or dysfucntion. We hypothesize that in individuals with abnormally 
high basal Drak2 expression (hit 2), less hit 1 might be sufficient to cause excessive cell 
damage or dysfunction.  
 
4. The signalling pathway of Drak2 
 
4.1 Pathways upstream of Drak2 
 
In islet β cells, Drak2 expression was increased after TNFα, IFNγ, IL-1β or free fatty 
acid treatment. Recent study shows the cytotoxic effect of IL-1β/IFNγ was associated 
with the expression of inducible nitric oxide synthase (iNOS) and production of nitric 
oxide. NG-monomethyl-L-arginine (L-NMMA) is an inhibitor of inducible nitric oxide 
synthase (iNOS) and production of nitric oxide. It can block the β cells death induced 
by IL-1β and IFNγ (7). In our study, when islets are treated with IL-1β and IFNγ in the 
presence of L-NMMA, the induced Drak2 expression by IL-1β and IFNγ is diminished 
by L-NNMA. This proved that iNOS is upstream of Drak2 in cytokine induced β cell 
apoptosis.   
 
4.2 Downstream of Drak2 
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Previously, we only know that Drak2 is a genuine substrate of itself. In this study, we 
identified 5 putative Drak2 substrates, and proved that p70S6 kinase (p70S6K) was 
Drak2 substrate in vitro and in vivo.  
The S6 kinases are members of the AGC family of serine/threonine protein kinases and 
are involved in the regulation of cell growth, survival and metabolism (8).  
Nowadays, there is increased interest of p70S6K’s role in diabetes. The pancreatic β-
cell has a unique ability to secrete insulin and also express a functional insulin receptor. 
The docking proteins of this receptor are insulin receptor substrate (IRS)-1 and -2, and 
the downstream signaling elements are mTOR and translational regulators PHAS-I and 
p70S6 kinase. Thus, p70S6K is the necessary component of the insulin signaling 
cascade to regulate insulin-mediated gene expression and protein translation in an 
autocrine manner (9). However, in parallel studies, it has become increasingly evident 
that p70S6K may also be implicated in a negative feedback loop to suppress insulin 
signaling. p70S6K may lead to insulin resistance by affecting IRS1 serine 
phosphorylation. In a homeostatic setting, as nutrients and amino acids are consumed, 
p70S6K activity participates in mediating cell growth. In contrast, under conditions of 
nutrient overload associated with the obese state, constitutive activation of p70S6K 
signaling leads to desensitization of insulin signaling through IRS1 serine 
phosphorylation and inhibition of IRS1 transcription. Thus, p70S6K may mediate 
insulin resistance, and potentially type 2 diabetes in the face of nutrient excess (10). 
In our study, we found that Drak2 mice are prone to type 2 diabetes when they are fed 
with high fat diet. It is possible that Drak2 overexpression leads to p70S6K constitutive 
activation and under conditions of nutrient overload; subsequently, the activation of 
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p70S6K signalling leads to insulin resistance. Our data also suggest that the activation 
of this pathway will lead to β cell apoptosis. 
By activating p70S6K through direct phosphorylation, mTOR is an important element 
in the activation scheme of p70S6K. Rapamycin prevents the phosphorylation of 
mTOR. It is a potent immunosuppressant that interferes with T-cell activation at the 
level of translation, and it has been, in part, responsible for the success of the Edmonton 
protocol in islet transplantation in type 1 diabetes (11). Moreover, recent study suggests 
that rapamycin increases basal and stimulated insulin levels in vivo and insulin content 
in vitro and reduce apoptosis in islet (12). Interestingly, islet transplantation efficiency 
has been greatly improved after rapamycin is introduced into the immunosuppressant 
regimen. It is conceivable that inhibition of p70S6K phosphorylation by rapamycin 
contributes to reduction of islet apoptosis after transplantation, and hence, is partially 
responsible for the increase in transplantation efficiency. We have further in vitro 
evidence that rapamycin renders β cells partially resistant to apoptosis, validating that 
p70S6K is indeed relevant to islet survival. It is possible that inflammatory cytokines 
activate both the Drak2/p70S6K and mTORC1/p70S6K pathways (Fig.2), and that 
inhibiting one of them is only partially effective in reducing β cell apoptosis. Indeed, 
when Drak2 upregulation stimulated by cytokines was prevented by siRNA, islet 
apoptosis was decreased, but was not totally prevented. Similarly, rapamycin only 
partially protected islet apoptosis from the cytokines. We tried rapamycin and Drak2 
siRNA combination, they showed a synergy in protecting human islet from apoptosis 
caused by cytokine treatment. Hence dual inhibition of mTORC1 (with rapamycin) and 
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Drak2 (with Drak2 inhibitors that are to be developed) might achieve better results in 
islet protection in terms of cytokine-induced β cell apoposis. 
 
Full activation of p70S6K requires multiple coordinated phosphorylation events. The 
first step in the phosphorylation sequence leading to activation is the mTOR-dependent 
phosphorylation of Ser 371 in the linker domain, as well as Ser 411, Ser 418, Thr 421 
and Ser 424, located in the carboxy-terminal autoinhibitory domain (13-16). The 
analogous residues in mouse p70S6k are Ser 394, Ser 434, Ser 441, Thr 444 and Ser 
447. Phosphorylation of Thr389 within a hydrophobic motif by the mTOR-Raptor 
complex allows docking of phosphoinoside-dependent kinase1 PDK1 (17;18), which 
phosphorylate Thr 229 (in the catalytic domain). This is the final phosphorylation event 
(19;20). Since Drak2 phosphorylates p70s6K, it will be interesting to know which 
p70S6k amino acid residues are the substrates of Drak2, and whether Drak2 and 
mTORC1 have overlapping phosphorylation repertoire on p70S6K. 
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5. A proposed model of Drak2 signalling 
 
Based on our data, we propose the following pathways involving Drak2 (Fig.2).  
 
In islet β cell, IFN-γ and IL-1β induce apoptosis by activating iNOS. Drak2 is 
downstream of iNOS, and it can phosphorylate p70S6k. mTOR activate p70S6K. 
Rapamycin, an inhibitor of mTOR, renders β-cells partially resistant to apoptosis 
induced by cytokines, suggesting that p70S6 kinase is relevant to islet apoptosis.  
We also found that FasL induced Drak2 expression in islets, and Drak2 Tg islets treated 
with FasL plus IFN-γ presented increased apoptosis, compared to WT islets (data not 
shown). It is known that islet β-cell apoptosis often needs concerted signals from 
different pathways. It is possible that Drak2 signaling pathway interacts with several 
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other apoptotic pathways, and these signalling pathways play a concerted effort on β-
cell apoptosis. We found that Drak2 acts through caspase-9 in apoptosis induced by 
cytokines. However, our study on the involvement caspase 8 and Bid cleavage in 
Drak2-mediated apoptosis was not conclusive. Further elucidating the relationship 
amongh these factors will be needed to better understand the full cascade of Drak2 
signaling in apoptosis induction.  
  
We found that p70S6 kinase, a key regulator of cell size and cell cycle, is a substrate of 
Drak2. In the future, we will validate other 4 putative Drak2 substrates identified by our 
protein kinase substrate array. Considering the multiple substrates of Drak2 and its 
broad expression pattern in the embryonic stage and non-lymphoid organs, it’s possible 
that further study on Drak2 will show us a more complicated network of Drak2 
signaling in various cells and organs.  
 
 
6. Summary and further perspectives 
Our study demonstrates that Drak2 is a pro-apoptotic factor in both T cells and islet 
β cells. It plays important roles in memory T-cell development and diabetes 
pathogenesis. We have identified 5 putative Drak2 substrates, and proved that p70S6K 
is a bona fide Drak2 substrate in vitro and in vivo.  
For the further investigation, firstly, we plan to identify which amino acid residue(s) of 
p70S6K is phosphorylated by Drak2. p70S6K has multiple functions in cell growth, 
survival, apoptosis and protein translation. Finding out its residue(s) phosphorylated by 
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Drak2 will help us better understand the function of Drak2 in comparison to mTOR, 
another kinase capable of phosphorylating p70S6K. We will know then whether they 
have overlaping or different effect on p70S6K activation. 
Secondly, it’s intriguing that both Tg and KO mice of Drak2 have increased T-cell 
apoptosis. It’s possible that Drak2 plays different roles in extrinsic and intrinsic 
apoptosis pathways, which were tested separately in Tg and KO T cells by us and the 
group in San Diego. To confirm our hypothesis, we could using the Tg and KO T cells 
in the same experiment of extrinsic or intrinsic apoptosis induction, to ascertain that 
they behave differently.   
We will also try to validate other 4 putative Drak2 substrates identified by our protein 
kinase substrate array. It is possible that Drak2 has different functions when it 
phosphorylates different sustrates. Cyclin dependent kinase 3 (CDK3) is among the 4 
other putative Drak2 substrates identified by the array. CDKs are a family of 
serine/threonine kinases involved in the regulation of cell cycle. Little is known about 
CDK3, which is a homolog of CDK2 and cell division cycle kinase 2 (CDC2). Previous 
studies using ectopic expression of human CDK3 suggest a role for this kinase in the 
G(1)/S-phase transition (21;22). If CDK3 is confirmed to be another substrate of Drak2, 
we might discover additional Drak2 function in cell cycle progression. 
Lastly, we are very much intereated in developping Drak2 inhibitors, as they could be 
used as therapeutic agents/drugs for preventing or delaying the onset of T1D and T2D. 
Since we have produced recombinant Drak2 and identified p70S6K as its substrate, the 
screening of Drak2 inhibitors from a suitable small molecule compound bank is a quite 
feasible task. 
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7. Contributions to science 
1) We have corrected a previous misconception that Drak2’s expression is 
restricted in the T-cell compartment. We have found broad expression of Drak2 
at embryo stage and prominent signal in non-lymphoind organs in adult such as 
brain, stomach, skin and testis. This could provide a valuable guidance in the 
future to investigate the complete physiological role of Drak2.  
2) With the transgenic mouse model, we found activated Drak2 Tg T cells 
demonstrated significantly enhanced apoptosis in the presence of exogenous IL-
2, which is accompanied with a compromised memory T-cell response. This 
also corrected an erroneous conclusion by another group that Drak2 is not 
involved in apoptosis at that time. 
3) We also found that Drak2 overexpression in Tg mouse led to aggravated β-cell 
apoptosis triggered by cytokine or free fatty acid stimuli. Further in vivo 
experiments demonstrated that Drak2 Tg mice were prone to T1D in a multiple-
low-dose STZ-induced diabetes model, and prone to T2D in a diet-induced 
obesity model, indicating that Drak2 is a contributing risk factor to T1D and 
T2D.  
4) We established that inducible nitric oxide synthase was upstream and caspase-9 
was down stream of Drak2. We also identified p70S6K as a novel substrate of 
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Drak2. These findings illustrated the signalling pathway of Drak2 and are 
essential in developping therapeutic compounds for diabetes.  
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